https://trial.medpath.com/news/4092a70a283af95f/cms-launches-generous-model-to-implement-most-favored-nation-pricing-for-medicaid-prescription-drugs 2025-11-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/11c3684d11563759/forbion-closes-eur200-million-bioeconomy-fund-to-drive-sustainable-biotechnology-innovation 2025-11-07T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/21c64e332723eaa4/mark-cuban-s-cost-plus-drugs-adds-starjemza-biosimilar-to-specialty-medicine-portfolio 2025-11-07T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/2c86f6856832466d/fda-505-b-2-pathway-drives-69-drug-reformulations-in-2024-2025-focusing-on-stability-and-patient-experience 2025-11-07T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/bb598ff2eb03bf26/protagonist-therapeutics-advances-multiple-drug-programs-with-strong-financial-position-through-2028 2025-11-07T01:19:48+00:00 hourly 0.9 https://trial.medpath.com/news/5dfbf8b8e76be2fb/moffitt-researchers-develop-injectable-biomaterial-to-create-tumor-fighting-immune-structures 2025-11-07T01:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/82b4b0ec8720a8b9/nchroma-bio-s-epigenetic-therapy-crma-1001-shows-promise-as-potential-functional-cure-for-chronic-hepatitis-b 2025-11-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2dbd78d2945503a/fda-leadership-turmoil-escalates-as-richard-pazdur-takes-cder-helm-amid-pfizer-novo-bidding-war 2025-11-06T21:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbb9fd79f0934a90/cue-biopharma-and-immunoscape-partner-on-novel-seed-and-boost-cell-therapy-for-solid-tumors 2025-11-06T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/95203a1a7217ac77/genmab-reports-strong-q3-2025-results-with-key-pipeline-advances-and-8-billion-merus-acquisition 2025-11-06T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/a9f723ef17c1a7e1/revolutionary-protein-gel-successfully-regenerates-tooth-enamel-in-laboratory-tests 2025-11-06T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/ee46a7b86c8a3294/gh-research-s-mebufotenin-therapy-gh001-shows-73-remission-rate-in-treatment-resistant-depression 2025-11-06T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/eb43ef90d80f261b/rockefeller-scientists-engineer-next-generation-antibody-100-times-more-potent-than-ivig-for-autoimmune-diseases 2025-11-06T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/8415f13b00ecd345/cannformatics-receives-irb-approval-for-medical-cannabis-study-in-dementia-patients 2025-11-06T17:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/82ac5635096f3a42/axsome-therapeutics-acquires-novel-gaba-a-receptor-modulator-azd7325-for-epilepsy-treatment 2025-11-06T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/7bdaaf311403cf38/chemomab-s-nebokitug-shows-sustained-anti-inflammatory-effects-in-48-week-psc-extension-study 2025-11-06T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/0ef3c7cc3fc88d23/urteste-launches-european-clinical-trial-for-urine-based-pancreatic-cancer-detection-test 2025-11-06T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/7deecb3b20f0e68e/black-diamond-therapeutics-prepares-to-release-phase-2-data-for-silevertinib-in-egfr-mutant-nsclc 2025-11-06T17:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/590e4e7927f63caa/biovectra-and-revolution-biomanufacturing-form-strategic-partnership-for-integrated-mrna-development-and-manufacturing 2025-11-06T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/9a35ecde25df0189/elephas-biosciences-secures-40m-series-b-2-funding-to-launch-live-tumor-profiling-platform-for-immunotherapy-response-prediction 2025-11-06T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/987703df00228d25/ianalumab-ibrutinib-combination-enables-treatment-free-periods-for-chronic-lymphocytic-leukemia-patients 2025-11-06T17:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/9877f459216c0f25/pim3-inhibition-restores-car-t-cell-function-in-hypoxic-solid-tumors 2025-11-06T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/9609fe60d126182f/medicenna-partners-with-italian-foundation-to-launch-neo-cyt-trial-testing-mdna11-in-high-risk-melanoma 2025-11-06T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/d7b7dc083c77e3c6/intranasal-h5n1-vaccine-shows-broad-immune-response-in-phase-i-trial 2025-11-06T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/ad3294a70e84c79a/astrazeneca-acquires-sixpeaks-bio-for-300m-to-advance-muscle-preserving-obesity-treatments 2025-11-06T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/34bdb9037273f1c9/accipiter-biosciences-emerges-with-12-7m-seed-funding-to-develop-ai-designed-de-novo-protein-therapeutics 2025-11-06T17:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/a7788534f13c14a6/palatin-advances-oral-mc4r-agonist-pl7737-for-obesity-treatment-with-promising-preclinical-data 2025-11-06T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/3c92230a7862a4cf/biomerica-expands-cdmo-services-to-capture-growing-diagnostic-development-market 2025-11-06T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/e0943287e42e42c6/debiopharm-completes-enrollment-for-first-ever-yearly-injectable-triptorelin-formulation-in-pediatric-central-precocious-puberty-trial 2025-11-06T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/8ac91aa7dccfba8d/noema-pharma-s-cendifensine-shows-92-reduction-in-menopausal-hot-flashes-in-phase-2a-trial 2025-11-06T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/87167e52c4c6c2b7/montai-therapeutics-advances-first-in-class-oral-nrf2-agonist-for-ulcerative-colitis-to-ind-enabling-studies 2025-11-06T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/0f4be4db0d3eb6d7/finerenone-shows-promise-as-first-new-type-1-diabetes-kidney-treatment-in-30-years 2025-11-06T17:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/a3e64becaf64f5be/caredx-launches-histomap-kidney-tissue-based-test-to-enhance-transplant-rejection-diagnosis 2025-11-06T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/f1ead9550d234880/sangamo-therapeutics-advances-fabry-disease-gene-therapy-toward-fda-submission-following-positive-clinical-data 2025-11-06T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/a0ad793edeed8e01/who-releases-global-research-agenda-to-address-critical-gaps-in-pediatric-clinical-trials 2025-11-06T17:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/415aff2a928d7119/iavi-s-lassa-fever-vaccine-shows-promising-safety-and-immune-response-in-phase-1-trial 2025-11-06T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/8ca57054264ddb55/psyence-biomed-advances-phase-iib-psilocybin-trial-for-adjustment-disorder-in-palliative-care 2025-11-06T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/e5fab322e778abec/3d-bioprinting-technology-advances-toward-clinical-translation-with-new-material-innovations-and-therapeutic-applications 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eabde592734143c7/mitochondrial-priming-emerges-as-key-determinant-for-car-t-nk-cell-immunosenolytic-therapy-success 2025-11-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb465099985f8e41/real-world-study-shows-vibrant-system-delivers-sustained-relief-for-chronic-constipation-with-minimal-side-effects 2025-11-06T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f4c093cd560357f/dual-breakthrough-studies-advance-stem-cell-based-bone-regeneration-for-spinal-fractures-and-bone-defects 2025-11-06T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/127e5b28e4011e41/bright-minds-biosciences-launches-phase-2a-trial-for-novel-prader-willi-syndrome-treatment 2025-11-06T13:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/7a219dbf48c1485f/bioversys-initiates-phase-1-trial-of-bv100-in-china-targeting-critical-antimicrobial-resistance-crisis 2025-11-06T13:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/8e01a429798fc1a5/celltrion-acquires-kaigene-s-novel-autoimmune-antibody-therapeutics-in-744-million-deal 2025-11-06T13:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/af0bbb720322f16d/arcoris-bio-raises-chf-6-3-million-to-advance-muse-nanotechnology-platform-for-digital-pathology 2025-11-06T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/8822220e93f6cf2f/zydus-receives-fda-orphan-drug-designation-for-desidustat-in-beta-thalassemia-treatment 2025-11-06T13:18:29+00:00 hourly 0.9 https://trial.medpath.com/news/bfb4894594d16256/new-zealand-introduces-fast-track-approval-amendments-to-accelerate-supermarket-development-and-reduce-healthcare-access-barriers 2025-11-06T13:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/f8c2a0d2663dccec/marksans-pharma-secures-uk-mhra-approval-for-exemestane-breast-cancer-treatment 2025-11-06T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/a787417ceb9825c8/nanotemper-acquires-envue-technologies-and-launches-dianthus-a-to-advance-single-molecule-drug-discovery 2025-11-06T13:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/a6b7c48704f02cce/lungpacer-medical-initiates-stari-trial-for-next-generation-diaphragm-neurostimulation-in-critically-ill-patients 2025-11-06T09:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/a4a60243053484fe/illuminare-biotechnologies-rizedisben-shows-promise-for-nerve-visualization-in-prostate-cancer-surgery 2025-11-06T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/271d57ae459ce8fc/rhythm-pharmaceuticals-secures-public-reimbursement-for-imcivree-in-five-canadian-provinces 2025-11-06T09:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/4b51e15f57711e5e/mwyngil-therapeutics-licenses-gpr75-modulators-for-novel-obesity-and-diabetes-treatment-approach 2025-11-06T04:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/938a2007afdc5287/fda-issues-18-warning-letters-to-companies-illegally-marketing-unapproved-botulinum-toxin-products 2025-11-06T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/47e1b396e4356418/gossamer-bio-advances-seralutinib-phase-3-trials-with-prosera-results-expected-february-2026 2025-11-06T01:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/eabe484028300458/dynavax-secures-exclusive-license-to-vaxart-s-oral-covid-19-vaccine-in-25-million-deal 2025-11-06T01:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/06006275e6086549/lumonus-secures-a-25-million-series-b-to-expand-ai-powered-radiation-oncology-platform-globally 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b0b5f8eca415eef0/samsung-bioepis-secures-japanese-approval-for-ustekinumab-biosimilar-expands-global-autoimmune-treatment-access 2025-11-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93d3be68244a279f/foghorn-therapeutics-advances-multi-target-protein-degrader-pipeline-with-fhd-909-phase-1-trial-progressing 2025-11-05T22:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/2d03760db431ea26/next-oncology-expands-phase-i-cancer-trial-network-to-japan-through-kansai-medical-university-partnership 2025-11-05T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/ef6ae3e7213b30dc/processa-pharmaceuticals-to-present-adaptive-phase-2-3-study-of-pcs499-for-rare-kidney-disease-fsgs-at-asn-kidney-week-2025 2025-11-05T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/news/3adf4bbd89129135/avant-technologies-and-sgaustria-launch-joint-venture-to-develop-stem-cell-based-diabetes-therapy 2025-11-05T22:51:46+00:00 hourly 0.9 https://trial.medpath.com/news/f2c9653ec7e2afde/normunity-doses-first-patient-with-novel-t-cell-engager-nrm-823-in-phase-1-solid-tumor-trial 2025-11-05T22:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/63f3ca9428de107c/immune-checkpoint-inhibitors-demonstrate-safety-and-efficacy-for-nsclc-treatment-in-hiv-positive-patients 2025-11-05T22:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/44c29c263882dacc/palvella-therapeutics-announces-qtorin-pitavastatin-for-rare-skin-disease-dsap-with-no-current-fda-approved-treatments 2025-11-05T22:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/17dcc81789c0bab7/sonothera-demonstrates-novel-ultrasound-gene-delivery-for-x-linked-alport-syndrome-treatment 2025-11-05T22:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/f247faa34f88db8c/touchlight-expands-mbdna-platform-with-three-new-circular-dna-architectures-for-gene-therapy 2025-11-05T22:48:34+00:00 hourly 0.9 https://trial.medpath.com/news/27476c5d98432ebe/ai-achieves-atomic-precision-in-antibody-design-revolutionizing-drug-discovery 2025-11-05T22:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/ac9386728919c0dd/lunai-bioworks-ai-platform-achieves-94-accuracy-in-neurotoxic-compound-detection-using-zebrafish-models 2025-11-05T22:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/afdd4b6b230b740b/fda-approves-first-pediatric-treatment-for-irritable-bowel-syndrome-with-constipation 2025-11-05T22:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/bad558da8181ffa2/sotio-s-sot106-adc-shows-promise-in-sarcoma-treatment-with-strong-preclinical-results 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c680aba072f20401/ananda-scientific-partners-with-benta-to-advance-ptsd-treatment-development-in-europe-and-mena 2025-11-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcbbbe5d2c0daa1d/chinese-researchers-discover-nicotinamide-s-cardioprotective-effect-against-pd-1-inhibitor-toxicity 2025-11-05T21:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/df39539749f2a780/pacbio-hifi-sequencing-achieves-100-detection-rate-for-pathogenic-variants-in-multi-center-clinical-study 2025-11-05T17:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/576b77c38c0fedc1/moberg-pharma-partners-with-karo-healthcare-to-launch-breakthrough-topical-nail-fungus-treatment-across-europe 2025-11-05T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/8a4ad0e1602c0249/phase-1-trial-shows-ppv-06-vaccine-safely-targets-il-6-in-knee-osteoarthritis 2025-11-05T17:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/9a9ee08c711ad082/jupiter-neurosciences-receives-fda-ind-clearance-for-jotrol-phase-2a-trial-in-parkinson-s-disease 2025-11-05T17:43:58+00:00 hourly 0.9 https://trial.medpath.com/news/717b780dacdfc60f/verismo-therapeutics-novel-kir-car-platform-shows-enhanced-safety-and-efficacy-in-solid-tumor-preclinical-studies 2025-11-05T17:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/e35dbbd1893e14c5/maat-pharma-s-maat034-shows-83-7-tumor-growth-reduction-in-preclinical-studies-at-sitc-2025 2025-11-05T17:43:51+00:00 hourly 0.9 https://trial.medpath.com/news/f2e5f71b05627c5e/nona-biosciences-expands-car-t-partnership-with-umoja-biopharma-to-develop-in-vivo-cell-therapies 2025-11-05T17:43:23+00:00 hourly 0.9 https://trial.medpath.com/news/557129416f37ca2e/india-launches-world-s-first-humanized-car-t-therapy-nexcar19-for-cancer-treatment 2025-11-05T17:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/584e5d3a402dd90b/tennessee-oncology-launches-dedicated-early-phase-clinical-research-unit-to-expand-community-access-to-experimental-cancer-therapies 2025-11-05T17:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/0d2fbd343798f131/biomarker-partnerships-surge-as-precision-medicine-drives-strategic-collaborations 2025-11-05T17:42:04+00:00 hourly 0.9 https://trial.medpath.com/news/0073500b6c16e8b8/tenpoint-therapeutics-submits-first-international-nda-for-brimochol-pf-presbyopia-treatment-in-south-korea 2025-11-05T17:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/683205a98066b573/jaya-biosciences-secures-u-s-patent-for-gene-therapy-approach-to-alzheimer-s-disease-treatment 2025-11-05T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/fb7ff9b1649d6b2f/world-s-first-egfr-targeted-adc-receives-approval-in-china-for-nasopharyngeal-carcinoma 2025-11-05T17:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/f0a2bcef4bedd6b9/recursion-achieves-500m-partnership-milestone-with-novel-microglial-cell-map-for-neurological-disease-research 2025-11-05T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/0721b86cbd3566a6/atea-pharmaceuticals-advances-hcv-phase-3-program-with-new-dual-mechanism-data-and-expands-pipeline-to-hepatitis-e 2025-11-05T17:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/ecf50bd18510f687/recursion-appoints-new-ceo-as-ai-drug-discovery-pioneer-faces-market-pressures 2025-11-05T17:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/015da0365a1dd352/anika-therapeutics-submits-final-pma-module-for-hyalofast-cartilage-repair-scaffold-despite-mixed-phase-iii-results 2025-11-05T17:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/f26d4d09d9698f6a/polyactiva-and-raresight-partner-to-develop-first-in-class-treatments-for-rare-pediatric-retinal-diseases 2025-11-05T17:38:24+00:00 hourly 0.9 https://trial.medpath.com/news/e34cff8c9bd72b0f/fda-approves-first-ever-robotic-microsurgical-study-for-alzheimer-s-disease-treatment 2025-11-05T17:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/b6dc0484328db820/lunai-bioworks-reports-complete-tumor-regression-with-second-generation-dendritic-cell-therapy-in-pancreatic-cancer-models 2025-11-05T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/c061f78f74919da9/st-jude-scientists-develop-risk-stratification-system-to-reduce-medulloblastoma-treatment-toxicity 2025-11-05T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/08656beb788062f0/health-canada-approves-vyvgart-sc-as-first-novel-cidp-treatment-in-three-decades 2025-11-05T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/e696bd097bab6338/victor-trial-shows-neutral-primary-outcome-for-vericiguat-in-stable-heart-failure-patients 2025-11-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/54173aff8a3ba4e9/moonlake-s-sonelokimab-shows-promise-in-palmoplantar-pustulosis-phase-2-trial-advances-toward-bla-submission 2025-11-05T14:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/f5225cf5b9f4413c/recursion-pharmaceuticals-names-najat-khan-as-new-ceo-in-leadership-transition 2025-11-05T14:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/048ff691a33d32b7/pre-treatment-lung-abnormalities-emerge-as-major-risk-factor-for-t-dxd-pneumonitis-in-metastatic-breast-cancer 2025-11-05T14:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/556dd0b47cc3822d/lift-biosciences-unveils-promising-preclinical-data-for-first-in-class-neutrophil-cell-therapy-at-sitc-2025 2025-11-05T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/news/7477c1bdf0ca1063/fda-grants-orphan-drug-designation-to-leukogene-s-m2t-cd33-for-acute-myeloid-leukemia-treatment 2025-11-05T14:44:03+00:00 hourly 0.9 https://trial.medpath.com/news/e63bb73aee40fb23/cellbxhealth-demonstrates-compatibility-between-parsortix-platform-and-roche-s-automated-staining-system-for-adc-target-analysis 2025-11-05T10:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/ffb629e39de69614/biomea-fusion-reports-sustained-diabetes-efficacy-with-icovamenib-and-advances-obesity-pipeline-with-bmf-650 2025-11-05T10:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/7742f250873cb09b/fda-approves-restylane-lyft-for-chin-enhancement-expanding-hyaluronic-acid-filler-applications 2025-11-05T10:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/6dbf49ff3c2c4b47/icr-researchers-develop-novel-formulation-strategies-to-enable-oral-delivery-of-vhl-based-protacs 2025-11-05T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/400143f43d94890a/mesoblast-secures-fda-meeting-to-discuss-opioid-cessation-data-for-chronic-back-pain-cell-therapy 2025-11-05T05:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/d4587d1c2877d412/johnson-johnson-s-shockwave-ivl-system-demonstrates-strong-one-year-outcomes-in-complex-peripheral-artery-disease-treatment 2025-11-05T05:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/93e5a1f41fe1ebab/large-scale-uk-study-shows-covid-19-infection-poses-greater-heart-risk-to-children-than-vaccination 2025-11-05T05:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/ec3cdaf7a4cb9bf5/colossal-biosciences-acquires-leading-animal-cloning-company-viagen-to-advance-de-extinction-platform 2025-11-05T05:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/fa2dfb4c640f1fbc/fda-issues-complete-response-letter-for-biohaven-s-vyglxia-troriluzole-for-spinocerebellar-ataxia 2025-11-05T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/c3c38e01dc3cb375/renerve-expands-clinical-trial-for-fda-cleared-nervalign-nerve-cuff-following-positive-interim-results 2025-11-05T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/deef42b73e6f12b7/relmada-therapeutics-raises-100-million-to-advance-oncology-and-cns-pipeline 2025-11-05T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/312f20e4e0d44065/qol-medical-to-acquire-evoke-pharma-for-11-per-share-securing-gimoti-nasal-spray-for-diabetic-gastroparesis 2025-11-05T01:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/ae9f0628dc176c2b/bullfrog-ai-s-precision-oncology-platform-identifies-patient-subtypes-for-enhanced-glufosfamide-response-in-pancreatic-cancer 2025-11-05T01:23:18+00:00 hourly 0.9 https://trial.medpath.com/news/52e1d605dc3ea09a/pretzel-therapeutics-unveils-polrmt-as-novel-obesity-target-with-promising-preclinical-results 2025-11-05T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/de5ad757e3ef7d79/eilean-therapeutics-first-in-class-malt1-degrader-te205-shows-promising-efficacy-in-ulcerative-colitis-preclinical-studies 2025-11-05T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/c91418e9adb78ca2/phase-3-trial-shows-stem-cell-therapy-reduces-heart-failure-risk-by-57-after-heart-attack 2025-11-05T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/8d2dfc66f15cf089/metavia-s-da-1726-shows-promising-weight-loss-results-in-phase-1-trial-with-superior-lipid-benefits 2025-11-05T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/0fd81b82bbb8ba4b/arena-bioworks-shuts-down-after-less-than-two-years-citing-policy-uncertainty-and-funding-challenges 2025-11-05T01:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/d05fe50c189d8ff4/first-ras-inhibitor-shows-clinical-promise-for-nras-mutant-melanoma-patients 2025-11-05T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/3f2eaa4dc1546b62/stoke-therapeutics-advances-phase-3-dravet-syndrome-trial-with-strong-financial-position-through-2028 2025-11-05T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/e1b2d89ab0617483/memorial-sloan-kettering-and-yale-cancer-center-deploy-triomics-ai-platform-to-accelerate-clinical-trial-matching 2025-11-05T01:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/f2983a76725ff7f9/doxycycline-shows-30-35-reduction-in-schizophrenia-risk-among-finnish-adolescents 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9979a89e25d4add5/corvus-pharmaceuticals-reports-promising-phase-1-1b-results-for-soquelitinib-in-t-cell-lymphoma-at-ash-2025 2025-11-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a931502cd7087e52/largest-wearable-defibrillator-study-demonstrates-100-conversion-success-in-21612-patients 2025-11-04T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/5b53a832f3a58654/pacira-biosciences-licenses-novel-long-acting-ropivacaine-formulation-amt-143-for-postsurgical-pain-management 2025-11-04T21:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/df5c79b71eaedf33/aveo-oncology-partners-with-hibercell-to-develop-first-in-human-perk-inhibitor-for-renal-cell-carcinoma 2025-11-04T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/f0dc7a0c3c8a212e/intrepid-alliance-launches-open-access-antiviral-toolbox-to-address-global-r-d-gaps 2025-11-04T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/ae7e114b6842ffdf/scilex-secures-10m-exclusive-license-for-ai-driven-biotech-asset-tokenization-platform 2025-11-04T21:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/675b8ef05fe6546c/ankyra-therapeutics-initiates-phase-1b-trial-of-anchored-il-12-immunotherapy-combined-with-checkpoint-blockade-in-lung-cancer 2025-11-04T21:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/e4a1a8ed3877b81c/five-year-zuma-5-data-shows-axicabtagene-ciloleucel-achieves-durable-responses-in-relapsed-refractory-indolent-non-hodgkin-lymphoma 2025-11-04T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/65a79fa23b1df357/storm-pe-trial-shows-mechanical-thrombectomy-superior-to-anticoagulation-alone-for-pulmonary-embolism 2025-11-04T21:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/612e900e92359ed0/defence-therapeutics-accum-kadcyla-shows-20-fold-efficacy-boost-in-her2-positive-breast-cancer-models 2025-11-04T21:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/3fdeaf2f9d4213eb/qiagen-acquires-parse-biosciences-for-225-million-to-expand-single-cell-analysis-capabilities 2025-11-04T21:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/3950529e050244d0/boehringer-ingelheim-secures-570m-licensing-deal-for-cdr111-trispecific-t-cell-engager-targeting-autoimmune-diseases 2025-11-04T21:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/fcf7759bb03a6460/aqua-medical-receives-fda-ide-approval-for-breakthrough-endoscopic-type-2-diabetes-treatment 2025-11-04T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/ca9ca466610b9b75/castle-biosciences-launches-advancead-tx-gene-expression-test-to-guide-atopic-dermatitis-treatment-selection 2025-11-04T21:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/950246e4f6dc0c28/hims-hers-and-novo-nordisk-in-talks-for-wegovy-distribution-partnership 2025-11-04T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/8b27f4b54d47506c/eva-pharma-launches-major-cancer-drug-manufacturing-facility-in-egypt-to-address-growing-oncology-burden 2025-11-04T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/cbf7a2ad56152d82/chiesi-discontinues-copd-drug-tanimilast-after-phase-iii-trial-failure 2025-11-04T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/81a00d67297c1140/biovac-opens-advanced-vaccine-development-laboratory-in-cape-town-to-strengthen-africa-s-manufacturing-independence 2025-11-04T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/5c5608a722367c55/kamada-initiates-shield-trial-to-prevent-late-cmv-infection-in-high-risk-kidney-transplant-recipients 2025-11-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/b46a99d51355104b/alkem-foundation-partners-with-iit-bombay-to-establish-india-s-first-immunotherapy-research-centre 2025-11-04T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/75dc1a6f443bc2a4/pacbio-s-sequel-ii-cndx-becomes-world-s-first-clinically-approved-long-read-sequencer-in-china 2025-11-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/1a6af5e2eb3f39b5/reset-trial-shows-sprint-pns-delivers-superior-pain-relief-for-chronic-low-back-pain-compared-to-standard-care 2025-11-04T17:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/8e901a30a47b1707/castlevax-initiates-phase-2-trial-of-intranasal-covid-19-vaccine-targeting-mucosal-immunity 2025-11-04T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/b249a59607fad494/azalea-therapeutics-launches-with-82-million-to-pioneer-in-vivo-car-t-cell-engineering 2025-11-04T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/00601a79164e1acc/grit-biotherapeutics-in-vivo-car-t-therapy-gt801-selected-for-oral-presentation-at-ash-2025 2025-11-04T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/2ecd17f0c15406b3/royalty-pharma-acquires-310-million-amvuttra-royalty-interest-from-blackstone-life-sciences 2025-11-04T17:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/ecdd61a5c8fa9124/cytomx-reports-promising-phase-1-biomarker-data-for-cx-801-in-advanced-melanoma-at-sitc-2025 2025-11-04T17:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/d5f7511cbb1f537a/ignite-biomedical-and-liquid-biosciences-discover-ai-driven-biomarkers-for-autism-spectrum-disorder-diagnosis-and-treatment 2025-11-04T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/3e7dac2062a225b0/crescent-biopharma-s-cr-001-bispecific-antibody-shows-cooperative-pharmacology-in-preclinical-studies 2025-11-04T17:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/728b93b46a4e092f/britecyte-receives-1m-maryland-grant-to-advance-novel-adipose-tissue-therapy-for-osteoarthritis 2025-11-04T17:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/d511b6af7a152575/basilea-receives-30-million-milestone-payment-as-cresemba-antifungal-sales-surge-27-globally 2025-11-04T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/bc5539fd759a28e7/medunik-usa-expands-medicaid-coverage-for-pheburane-in-rare-disease-treatment-access-initiative 2025-11-04T17:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/ef1af563fd20e945/expert-consensus-validates-clinical-potential-of-circulating-tumor-cells-highlights-parsortix-platform-as-leading-technology 2025-11-04T17:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/1cb2ae49a6d82a57/phenomix-sciences-validates-myphenome-test-for-predicting-glp-1-response-across-diverse-patient-populations 2025-11-04T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/a91e6712822d8b4f/fda-approves-fosfomycin-injection-for-complicated-urinary-tract-infections 2025-11-04T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/1402a6703d63bcba/morari-launches-fda-cleared-neurostimulation-patch-for-men-s-sexual-wellness-in-twin-cities 2025-11-04T17:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/9755ddf451e9e089/neok-bio-emerges-with-75m-to-develop-dual-targeting-adcs-for-cancer-treatment 2025-11-04T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/d4ba3b4830a77d7d/merck-assumes-full-control-of-mk-8690-anti-cd30-ligand-antibody-for-inflammatory-bowel-disease 2025-11-04T17:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/474e11644bedae83/gut-microbiota-derived-metabolites-emerge-as-key-modulators-of-cancer-immunotherapy-efficacy 2025-11-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3cf15e240db538a/long-term-melatonin-use-linked-to-90-higher-heart-failure-risk-in-new-study 2025-11-04T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/cba106d85184871d/rhythm-pharmaceuticals-reports-strong-q3-2025-results-with-51-3m-imcivree-revenue-and-december-fda-decision-pending 2025-11-04T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/eb27af80ead9e4db/merck-secures-700-million-from-blackstone-to-advance-trop2-targeting-adc-across-15-phase-3-cancer-trials 2025-11-04T13:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/c15583eb5b682f19/compass-pathways-accelerates-comp360-depression-therapy-launch-by-9-12-months-following-fda-meeting 2025-11-04T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/c89a162ad87c77a4/estrella-immunopharma-s-eb103-achieves-100-complete-response-rate-in-high-risk-b-cell-lymphoma-patients 2025-11-04T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/4d538a6f45bc64a7/valneva-s-second-generation-zika-vaccine-shows-enhanced-immune-response-in-phase-1-trial 2025-11-04T09:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/30826ddd5b75de6b/senti-bio-to-present-updated-senti-202-clinical-data-at-ash-2025-showcasing-logic-gate-technology-in-aml-treatment 2025-11-04T05:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/d93c666d62d453aa/orsobio-s-tlc-6740-combination-therapy-achieves-51-greater-weight-loss-than-tirzepatide-alone-in-phase-1b-2a-trial 2025-11-04T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/a028d20b24b920bc/incyte-showcases-first-in-class-mutant-calreticulin-antibody-inca033989-at-ash-2025-with-over-50-presentations 2025-11-04T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/d658688bb3dbc302/sarepta-s-essence-study-shows-mixed-results-for-duchenne-muscular-dystrophy-therapies-despite-missing-primary-endpoint 2025-11-04T01:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/05082ed7852805b2/artiva-biotherapeutics-reports-favorable-safety-profile-for-allonk-cell-therapy-in-32-autoimmune-disease-patients 2025-11-04T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/15533cc400d7c76e/covid-19-vaccination-reduces-long-covid-risk-by-36-in-adolescents-recover-study-shows 2025-11-04T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/2604f60f1483833a/amgen-files-second-federal-lawsuit-against-colorado-s-historic-drug-price-ceiling-on-enbrel 2025-11-04T01:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/af89d99bf29c5a0f/sarepta-s-duchenne-gene-therapy-fails-to-meet-primary-endpoint-in-nine-year-clinical-trial 2025-11-04T01:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/8aec6e7aa2d27792/duvakitug-shows-promising-efficacy-in-first-anti-tl1a-trial-for-crohn-s-disease 2025-11-04T01:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/07d79af17558f2db/dbv-technologies-appoints-kevin-trapp-as-chief-commercial-officer-ahead-of-viaskin-peanut-patch-bla-submission 2025-11-04T01:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/f7b0b78eeef838b2/transcon-pth-shows-sustained-kidney-function-improvements-in-3-year-hypoparathyroidism-study 2025-11-04T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/c9306ffec8754e9a/painless-trial-launches-home-based-brain-stimulation-study-for-cancer-pain-management 2025-11-04T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/e7fd6778949b6e18/agamree-shows-superior-safety-profile-with-comparable-efficacy-to-standard-corticosteroids-in-five-year-dmd-study 2025-11-04T00:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd8ce6e9a4de9cf8/star-therapeutics-reports-positive-phase-1-2-data-for-vga039-in-von-willebrand-disease-at-ash-2025 2025-11-03T21:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/cc5eda1ca0eb8bec/legend-biotech-to-present-comprehensive-carvykti-data-and-first-in-human-allogeneic-car-t-results-at-ash-2025 2025-11-03T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/0914af645ebcf09a/phio-pharmaceuticals-ph-762-shows-promising-results-in-phase-1b-skin-cancer-trial-with-37-5-complete-response-rate 2025-11-03T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/6a0d6004d0068281/recordati-rare-diseases-presents-nine-research-studies-on-rare-hematologic-disorders-at-ash-2025 2025-11-03T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/922c643cac86929c/ryvu-therapeutics-presents-promising-clinical-data-on-romaciclib-and-dapolsertib-at-ash-2025 2025-11-03T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/c74fd5f5223e6dfc/fluoguide-raises-sek-100-million-to-advance-cancer-surgery-drug-fg001-through-phase-ii-trials 2025-11-03T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/8c1cf93827858985/iit-madras-develops-ai-framework-pure-to-accelerate-drug-discovery-using-reinforcement-learning 2025-11-03T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/57f82230b2bd4a20/meharry-medical-college-and-novartis-launch-five-year-heart-initiative-to-combat-cardiovascular-disease-disparities 2025-11-03T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/05bf157aaa9ee81d/nautilus-biotechnology-achieves-milestone-with-first-external-field-evaluation-unit-for-alzheimer-s-research 2025-11-03T17:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/1dabb3c583e0fe18/tscan-therapeutics-secures-fda-agreement-for-tsc-101-pivotal-trial-implements-strategic-restructuring 2025-11-03T17:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/de2e870d6989c3af/altamira-therapeutics-expands-xphore-platform-with-successful-dna-delivery-technology 2025-11-03T17:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/67c10b13700c4b87/abcuro-s-ulviprubart-shows-promising-interim-results-in-rare-blood-cancer-t-lgll 2025-11-03T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/2d11518f08e89473/capricor-publishes-peer-reviewed-study-validating-deramiocel-s-anti-fibrotic-mechanism-for-duchenne-muscular-dystrophy 2025-11-03T17:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/e56fbe20ac0cae34/bioinvent-reports-promising-safety-and-efficacy-data-for-triple-combination-therapy-in-relapsed-refractory-non-hodgkin-s-lymphoma 2025-11-03T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/e85b73de8d3ac0a9/march-biosciences-to-present-interim-phase-2-data-for-first-in-class-cd5-targeted-car-t-therapy-at-ash-2025 2025-11-03T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/63efd8f4f3851e06/cullinan-therapeutics-reports-promising-30-response-rate-for-cln-049-t-cell-engager-in-relapsed-aml-patients 2025-11-03T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/576a5f4f7266c6a1/kimberly-clark-acquires-kenvue-for-48-7-billion-creating-consumer-health-giant 2025-11-03T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/7cb31dc8fdc9b9ef/genmab-presents-pivotal-phase-3-data-for-epcoritamab-at-ash-2025-expanding-treatment-options-across-b-cell-malignancies 2025-11-03T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/e7fcb599fb0424c1/benitec-biopharma-s-bb-301-gene-therapy-receives-fda-fast-track-designation-for-opmd-treatment 2025-11-03T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/4482380006e4996f/moderna-doses-first-patient-in-phase-1-2-trial-of-novel-mrna-t-cell-engager-for-multiple-myeloma 2025-11-03T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/759335453cc1d7cf/akums-drugs-secures-20-year-patent-for-dual-release-ppi-technology-targeting-gerd-treatment 2025-11-03T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/5e62e7c196337861/orna-therapeutics-to-present-in-vivo-car-t-data-at-ash-2025-plans-clinical-trial-application-for-cd19-program 2025-11-03T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/8a46901266650988/icecure-s-cryoablation-combined-with-radiation-therapy-achieves-74-five-year-survival-in-stage-i-lung-cancer 2025-11-03T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/26a38803f31635b3/phio-pharmaceuticals-reports-promising-phase-1b-results-for-ph-762-in-cutaneous-squamous-cell-carcinoma 2025-11-03T17:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/7b7be9a781082217/evaxion-unveils-ai-designed-cancer-vaccine-evx-04-targeting-acute-myeloid-leukemia 2025-11-03T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/7026f738349831d8/ai-powered-spatial-biology-platforms-advance-predictive-biomarker-discovery-in-cancer-immunotherapy 2025-11-03T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/9b2dd6758f2f2e7e/crescent-biopharma-advances-pd-1-x-vegf-bispecific-antibody-cr-001-toward-phase-1-trial 2025-11-03T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/0dc6cfaccd4156cb/ileukon-receives-fda-clearance-for-phase-ii-trial-of-mrna-based-il-2-therapy-ilkn421h-in-advanced-nsclc 2025-11-03T17:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/75bc99f1f5b2a9e5/opus-genetics-gene-therapy-shows-promise-in-restoring-vision-for-inherited-blindness 2025-11-03T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/a5af8ff3783cff4d/life-biosciences-appoints-veteran-biotech-leader-david-guyer-to-board-as-company-prepares-for-first-human-trials 2025-11-03T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/5eeaa453b6fe3f62/roche-showcases-comprehensive-hematology-pipeline-at-ash-2025-with-46-abstracts-spanning-blood-disorders 2025-11-03T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/a11832636727318a/apnimed-s-sulthiame-shows-promise-in-phase-2-trial-for-obstructive-sleep-apnea-results-published-in-the-lancet 2025-11-03T17:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/251318bd718c2bed/sumitomo-pharma-reports-promising-clinical-data-for-enzomenib-and-nuvisertib-ahead-of-ash-2025 2025-11-03T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/01dc749d668990eb/theralase-s-rutherrin-shows-100-fold-cancer-cell-kill-enhancement-in-preclinical-studies 2025-11-03T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/e2b2307c3c6de9b5/igc-pharma-expands-ai-powered-drug-discovery-platform-for-alzheimer-s-disease-development 2025-11-03T17:19:48+00:00 hourly 0.9 https://trial.medpath.com/news/85a193f506f75bd4/vorasidenib-demonstrates-sustained-long-term-efficacy-in-idh-mutant-grade-2-glioma 2025-11-03T17:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/982338e63c2dca1d/kidney-week-2025-showcases-breakthrough-therapies-across-nephrology-with-eight-major-trial-updates 2025-11-03T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/212003e8ce8b5a39/iovance-reports-promising-26-response-rate-for-lifileucel-til-therapy-in-advanced-nsclc 2025-11-03T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/505879adc15bf235/doseme-acquires-firstline-to-create-integrated-clinical-decision-support-platform-for-antimicrobial-stewardship 2025-11-03T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/68b288f40d158422/femasys-secures-fda-approval-to-advance-final-phase-of-fembloc-pivotal-trial-for-non-surgical-permanent-birth-control 2025-11-03T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/fdc402a8f00f01ef/united-therapeutics-achieves-first-clinical-xenotransplantation-with-genetically-modified-pig-kidney-in-expand-trial 2025-11-03T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/e8b36fb2c24fe551/takeda-s-qdenga-dengue-vaccine-demonstrates-sustained-seven-year-protection-in-phase-3-trial 2025-11-03T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/4d39c8ad89a67c41/sanyou-bio-and-shanghai-zj-bio-tech-form-strategic-partnership-to-accelerate-biologics-development-through-ai-and-automation 2025-11-03T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/2d3dbf323aa6b872/nuclera-partners-with-solve-scientific-to-expand-eprotein-discovery-platform-access-in-australia-and-new-zealand 2025-11-03T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/81363974cc497599/boost-pharma-secures-eur3-1-million-to-advance-stem-cell-therapy-for-osteogenesis-imperfecta 2025-11-03T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/2da31cd2e5afed89/aavantgarde-secures-141-million-series-b-to-advance-gene-therapies-for-stargardt-disease-and-usher-1b-syndrome 2025-11-03T13:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/dd81d6d2b2a6c6b2/roche-partners-with-manifold-bio-in-2b-ai-driven-deal-to-overcome-blood-brain-barrier-for-neurological-diseases 2025-11-03T13:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/876c35a1f00aff09/bharat-biotech-launches-nucelion-crdmo-to-advance-cell-and-gene-therapy-manufacturing-in-india 2025-11-03T13:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/91b43bcb7b6a8a1b/stcube-reports-promising-phase-1b-results-for-btn1a1-targeted-therapy-in-metastatic-colorectal-cancer 2025-11-03T09:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/b4730d2e71e90593/south-korea-approves-first-epilepsy-drug-under-new-fast-track-review-process 2025-11-03T09:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/5aaa551458ad8761/ensurge-and-corning-partner-to-develop-ultra-high-energy-density-solid-state-microbatteries-for-medical-applications 2025-11-03T09:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/76682483a8de0f00/gc-biopharma-s-barythrax-becomes-world-s-first-recombinant-anthrax-vaccine-to-show-protective-immunity-in-phase-2-trial 2025-11-03T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/1dd0f495d13d082a/arctic-therapeutics-receives-ema-approval-for-phase-iia-study-of-at-001-in-alzheimer-s-disease 2025-11-03T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/214f5e53776d6c11/tuhura-biosciences-unveils-delta-opioid-receptor-as-novel-target-to-overcome-cancer-immunotherapy-resistance 2025-11-03T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/91d5bc2aca9b1fd5/samsung-establishes-new-holding-company-to-expand-beyond-biosimilars-into-next-generation-biotechnology 2025-11-03T05:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/9e5b733b118f0d98/fda-issues-complete-response-letter-for-alvotech-s-golimumab-biosimilar-avt05 2025-11-03T01:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/2d6467f460835e98/fda-drug-center-chief-george-tidmarsh-resigns-amid-ethics-probe-and-industry-lawsuit 2025-11-03T01:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/4c162e60b92a203a/gore-viabahn-fortegra-venous-stent-achieves-83-4-primary-patency-in-deep-venous-obstruction-trial 2025-11-03T01:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/f9316f6654978c99/sk-biopharmaceuticals-partners-with-interon-to-develop-first-in-class-autism-treatment-using-neuroimmune-approach 2025-11-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1dfbd7db2568d00d/aura-biosciences-bel-sar-shows-promise-in-non-muscle-invasive-bladder-cancer-phase-1-study 2025-11-02T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/885ab2a81f63c253/fate-therapeutics-reports-promising-phase-1-data-for-off-the-shelf-car-t-therapy-in-lupus 2025-11-02T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/f4901d83f36ceee1/henlius-biotech-achieves-breakthrough-in-gastric-cancer-immunotherapy-with-serplulimab-phase-3-success 2025-11-02T17:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/d3c65bcbb323cb2c/nigeria-secures-eur10-2-million-eu-partnership-to-boost-local-pharmaceutical-manufacturing 2025-11-02T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/c2065691080b3983/oncohost-advances-plasma-proteomics-for-nsclc-immunotherapy-monitoring-and-prediction 2025-11-02T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/24aa320366ed9bbc/fda-s-q-collar-approval-under-fire-as-internal-reviewers-warned-of-flawed-evidence 2025-11-02T17:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/b967116e69b4447c/pulsenmore-receives-fda-approval-for-first-home-use-ultrasound-device-for-pregnant-women 2025-11-02T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/23bbfddb36a03f57/upadacitinib-30mg-demonstrates-superior-efficacy-among-jak-inhibitors-for-atopic-dermatitis-while-safety-analysis-reveals-new-infection-risks 2025-11-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5189be31ba758a98/royal-united-hospitals-bath-launches-clinical-trial-testing-repurposed-drugs-for-lacunar-stroke-prevention 2025-11-02T13:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/8d44c348dc0b6b3e/statins-show-promise-in-protecting-cancer-patients-from-chemotherapy-related-cognitive-decline 2025-11-02T09:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/3c1c78a47847e934/invex-therapeutics-advances-presendin-phase-iii-trial-for-idiopathic-intracranial-hypertension-with-fda-guidance 2025-11-02T05:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/688d091946f38df6/rituximab-shows-higher-cmv-reactivation-risk-than-obinutuzumab-in-follicular-lymphoma-treatment 2025-11-02T01:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/378cf8759829012a/bassett-cancer-institute-launches-alpha-dart-clinical-trial-for-inoperable-pancreatic-cancer 2025-11-02T01:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/9eba03d7bec3da35/uk-government-launches-ps650000-obesity-study-targeting-scotland-s-most-deprived-communities 2025-11-01T21:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/a82b84ec1b6ddcf2/icmr-seeks-industry-partners-to-develop-indigenous-monoclonal-antibodies-against-deadly-nipah-virus 2025-11-01T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/f738b7ecb95d2d41/galapagos-appoints-new-board-directors-to-accelerate-business-development-strategy 2025-11-01T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/dbb839ee105539de/pharmadrug-acquires-40-stake-in-canurta-to-advance-botanical-therapeutics-for-als-and-neurodegenerative-diseases 2025-11-01T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/2047be59c054ca1e/stoke-therapeutics-advances-phase-3-emperor-trial-for-dravet-syndrome-treatment-with-supporting-natural-history-data 2025-11-01T17:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/46eec05955a34868/cybin-closes-175-million-financing-to-advance-phase-3-psychedelic-depression-treatment 2025-11-01T17:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/0891dbfaa4c4d807/pfizer-secures-early-antitrust-clearance-for-7-3-billion-metsera-acquisition-amid-novo-nordisk-s-competing-bid 2025-11-01T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/1909aee6bc8842aa/biotech-startup-secures-30-million-to-research-gene-edited-babies-despite-scientific-opposition 2025-11-01T01:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/4ee7a0d7dacb7491/novo-nordisk-pursues-metsera-acquisition-with-amended-proposal-to-strengthen-obesity-pipeline 2025-11-01T01:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/2b07ed15f8edea3d/fda-issues-form-483-to-hetero-labs-following-inspection-revealing-severe-gmp-violations-at-undisclosed-warehouse 2025-11-01T01:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/917e7b679ee800db/johnson-johnson-submits-fda-application-for-stelara-in-pediatric-ulcerative-colitis 2025-11-01T01:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/1f7a48f20128881e/fda-takes-enforcement-action-against-unapproved-pediatric-fluoride-supplements-citing-gut-microbiome-concerns 2025-10-31T21:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/b8d315ea2c855a2f/hrsa-approves-eight-drug-companies-for-340b-rebate-model-pilot-program-starting-january-2025 2025-10-31T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/7eae895f08d2ee9f/oral-salmonella-paratyphi-a-vaccine-demonstrates-73-efficacy-in-first-human-challenge-trial 2025-10-31T21:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/b69d7cc93add0d95/sensei-biotherapeutics-abandons-lead-cancer-drug-solnerstotug-despite-promising-phase-i-results 2025-10-31T21:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/16045f17fc282035/intensity-therapeutics-stock-surges-400-following-promising-phase-i-ii-data-for-int230-6-in-solid-tumors 2025-10-31T17:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/89c38ec3badbe3bc/imodern-trial-shows-immediate-vs-delayed-heart-attack-treatment-equally-safe-published-in-nejm 2025-10-31T17:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/958e8d9ebac6f904/alps-group-completes-1-6-billion-spac-merger-lists-on-nasdaq-to-advance-precision-medicine-platform 2025-10-31T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/578d4c928c452b4e/biostem-s-bioretain-allograft-shows-71-higher-healing-rate-in-diabetic-foot-ulcer-trial 2025-10-31T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/ec5a7ed19b274b73/biocardia-advances-phase-3-cardiamp-hf-ii-trial-with-first-patient-enrollment-at-university-of-wisconsin 2025-10-31T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/22f32adea62eddfe/nclat-rules-competition-commission-cannot-investigate-patent-protected-drug-pricing-disputes 2025-10-31T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/f365aac2a929d438/libtayo-gains-widespread-provincial-reimbursement-across-canada-for-advanced-nsclc-and-basal-cell-carcinoma 2025-10-31T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/63819060761c4269/stem-cell-therapy-shows-78-fracture-reduction-in-children-with-osteogenesis-imperfecta 2025-10-31T17:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/bb4fcc6b88cf3fc2/lilly-discontinues-p2x7-inhibitor-ly3857210-for-chronic-pain-after-phase-ii-failure 2025-10-31T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/0e979eb4328ede7d/hemlibra-demonstrates-exercise-related-bleeding-prevention-in-hemophilia-a-as-pfizer-reports-positive-phase-iii-baisis-results 2025-10-31T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/e72afab0eb1b8590/federal-cancer-trials-fill-critical-gaps-left-by-industry-funding-asco-analysis-reveals 2025-10-31T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/b361ae0326508d24/q4-2025-biotech-catalyst-monitor-identifies-20-key-pipeline-events-including-cytokinetics-aficamten-and-gsk-s-depemokimab 2025-10-31T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/dd5f61870f41f34c/vesper-bio-s-ves001-shows-95-increase-in-progranulin-levels-in-phase-ib-iia-trial-for-frontotemporal-degeneration 2025-10-31T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/e9bcaf061f66dcae/aspen-pharmacare-secures-eur25-million-settlement-in-mrna-manufacturing-dispute 2025-10-31T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/dd44cd90e9192e8c/b7-h3-targeted-adc-hs-20093-demonstrates-promising-efficacy-in-relapsed-refractory-sarcomas-receives-fda-breakthrough-designation 2025-10-31T13:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/e1cd1a4ac1640511/astrazeneca-s-gefurulimab-meets-phase-iii-endpoints-in-myasthenia-gravis-but-lags-behind-competitor-therapies 2025-10-31T13:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/a32bb20e17296c1b/union-therapeutics-publishes-biomarker-data-showing-orismilast-s-multi-pathway-anti-inflammatory-effects-in-psoriasis 2025-10-31T13:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/193514d73a758a58/forlong-biotechnology-initiates-phase-2-trial-of-il-15-superagonist-fl115-combined-with-bcg-for-non-muscle-invasive-bladder-cancer 2025-10-31T13:19:48+00:00 hourly 0.9 https://trial.medpath.com/news/7a569cd405d3a489/bausch-lomb-s-miebo-costs-40-times-more-than-european-equivalent-highlighting-regulatory-pricing-loopholes 2025-10-31T13:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/df528b4c037c52db/4dmt-secures-85-million-upfront-in-strategic-partnership-with-otsuka-for-gene-therapy-4d-150-in-asia-pacific 2025-10-31T09:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/98fdc35fdc34403c/nanobiotix-secures-71-million-royalty-financing-to-advance-cancer-nanotherapy-through-2028 2025-10-31T09:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/1a6f4cd009b219b0/breckenridge-launches-generic-everolimus-1mg-tablets-completing-full-strength-portfolio-for-transplant-patients 2025-10-31T05:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/6ee301cb7a4292c2/knight-therapeutics-launches-first-evening-dosed-adhd-treatment-jornay-pm-in-canada 2025-10-31T01:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/004a9b84e07b8f09/california-awards-27-million-to-expand-cell-and-gene-therapy-access-to-underserved-communities 2025-10-31T01:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/a51ab9ea077f8275/thiorphan-shows-promise-for-spinal-cord-injury-treatment-in-breakthrough-uc-san-diego-study 2025-10-31T01:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/30d32f6948d7c28a/curavit-accelerates-digital-therapeutic-trial-for-overactive-bladder-completing-recruitment-two-months-ahead-of-schedule 2025-10-31T01:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/471e7886fdacf8c1/form-bio-partners-with-weill-cornell-medicine-to-develop-gene-editing-therapy-for-alzheimer-s-disease 2025-10-30T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/63245b01e0809a3b/create-medicines-unveils-all-rna-t-cell-engineering-platform-retrot-for-in-vivo-car-therapy 2025-10-30T21:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/9244a0b6d9449804/federal-circuit-upholds-invalidation-of-merck-s-multiple-sclerosis-drug-patent 2025-10-30T21:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/b441859fd0025c1b/moderna-shares-surge-12-on-reports-of-potential-acquisition-or-partnership-talks 2025-10-30T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/46e5b5a52bbef120/oxford-study-shows-73-efficacy-for-first-paratyphoid-a-vaccine-candidate 2025-10-30T17:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/eb448c69c276f550/niraparib-maintenance-therapy-extends-quality-adjusted-survival-by-8-months-in-advanced-ovarian-cancer 2025-10-30T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/35827615bb417b51/ritedose-secures-fda-approval-for-generic-tobramycin-inhalation-solution-expanding-cystic-fibrosis-treatment-access 2025-10-30T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/0ece28659fdcbb9d/ibio-s-ibio-610-activin-e-antibody-shows-100-day-human-half-life-potential-for-twice-yearly-obesity-treatment 2025-10-30T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/249a52bd038d2ae5/prophylactic-antibiotics-reduce-clinically-relevant-wound-complications-after-obstetric-tears 2025-10-30T17:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/fa3531ab34e130a2/rovia-clinical-research-expands-network-with-new-mississippi-site-partnership 2025-10-30T17:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/2ecba93be6443ea1/forward-therapeutics-initiates-phase-1-trial-of-ft2109-second-generation-oral-tnf-inhibitor 2025-10-30T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/19fd2d78729c2735/mink-therapeutics-reports-durable-clinical-activity-for-agent-797-inkt-cell-therapy-in-advanced-solid-tumors 2025-10-30T17:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/5fe5783fdd45bc94/t-knife-therapeutics-to-present-preclinical-data-on-prame-targeted-tcr-t-therapy-tk-6302-at-sitc-2025 2025-10-30T17:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/ef48d3e19dca80fa/scientists-successfully-reprogram-pathogenic-t-cells-into-protective-regulatory-cells-for-autoimmune-disease-treatment 2025-10-30T17:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/4b8a274c3ad0d839/alys-pharmaceuticals-initiates-first-in-class-mast-cell-selective-c-kit-inhibitor-trial-for-chronic-urticaria 2025-10-30T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/99087edfeabb33ff/helex-secures-3-5m-seed-funding-to-develop-non-viral-gene-therapy-for-polycystic-kidney-disease 2025-10-30T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/a0fd6007563eb479/mallinckrodt-to-present-new-terlipressin-data-at-kidney-week-2025-for-hepatorenal-syndrome-treatment 2025-10-30T17:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/7df12d89372c979d/allergy-therapeutics-initiates-second-year-of-phase-iii-pediatric-grass-allergy-trial 2025-10-30T17:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/df22dee6f12d4fe0/stallergenes-greer-s-staloral-birch-achieves-primary-endpoint-in-pediatric-phase-iii-trial-for-allergic-rhinoconjunctivitis 2025-10-30T17:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/bce047ef3270ea63/eli-lilly-s-tirzepatide-franchise-becomes-world-s-top-selling-drug-surpassing-keytruda 2025-10-30T17:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/3e7ae5e86b4bce0d/university-of-liverpool-partners-with-cyanocapture-to-develop-carboxysome-based-drug-delivery-nanotechnology 2025-10-30T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/13cbcaf09c1697ca/breakthrough-nanobody-based-antivenom-shows-promise-against-17-african-snake-species 2025-10-30T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/ff4d5f954f721cec/intensity-therapeutics-reports-promising-phase-1-2-results-for-int230-6-in-advanced-metastatic-cancers 2025-10-30T17:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/5cc9fc3b8ccc587f/radiopharmaceutical-trials-experience-tenfold-growth-as-precision-oncology-field-expands 2025-10-30T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/81b032e31fb7b884/new-research-reveals-how-innate-immunity-drives-autoimmune-disease-pathogenesis 2025-10-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4779878839bb4077/traditional-chinese-medicine-shows-promise-as-cancer-vaccine-adjuvants-in-comprehensive-review 2025-10-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/24f3983c43d923e5/rani-therapeutics-to-present-bioequivalent-oral-semaglutide-data-at-obesityweek-2025 2025-10-30T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/87e7d9197a4e4168/pfizer-raises-metsera-acquisition-offer-to-86-25-per-share-amid-novo-nordisk-competition 2025-10-30T13:23:11+00:00 hourly 0.9 https://trial.medpath.com/news/b541f2a511945476/innocare-s-zurletrectinib-shows-90-response-rate-in-pediatric-ntrk-fusion-solid-tumors 2025-10-30T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0f8e70e01c555a2/boehringer-ingelheim-licenses-first-in-class-small-molecule-from-kyowa-kirin-for-autoimmune-disease-treatment 2025-10-30T13:22:13+00:00 hourly 0.9 https://trial.medpath.com/news/91a69134b06b672b/nice-reverses-course-on-abiraterone-recommends-generic-version-for-metastatic-prostate-cancer 2025-10-30T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/62d057d875d8fe44/rubedo-life-sciences-partners-with-svax-to-advance-anti-aging-drug-rls-1496-in-middle-east-phase-2-trials 2025-10-30T13:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/2dcc42c1f6a0188d/sparingvision-initiates-first-in-human-trial-of-gene-agnostic-therapy-spvn20-for-advanced-retinitis-pigmentosa 2025-10-30T13:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/1fee673f2601f99f/foundation-medicine-partners-with-manifold-to-enhance-ai-powered-drug-discovery-platform 2025-10-30T13:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/2b3c0acdecf64dbe/iorganbio-emerges-from-stealth-with-2m-funding-to-launch-ai-powered-cell-manufacturing-platform-cellforge 2025-10-30T09:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/d59f8ac3f1991fc5/tezepelumab-enables-oral-corticosteroid-reduction-in-severe-asthma-patients-wayfinder-trial-shows 2025-10-30T09:18:06+00:00 hourly 0.9 https://trial.medpath.com/news/0d3ab1ccf0e50d7b/gensight-biologics-secures-fda-authorization-for-expanded-access-treatment-of-rare-blinding-disease 2025-10-30T09:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/75f6ff1d896beab4/esmo-2025-highlights-major-advances-in-breast-cancer-treatment-across-all-subtypes 2025-10-30T08:30:19+00:00 hourly 0.9 https://trial.medpath.com/news/6ea2d960f7e58deb/bioharvest-sciences-partners-with-saffron-tech-to-revolutionize-production-of-world-s-most-expensive-spice-through-botanical-synthesis 2025-10-30T06:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/7222a34b12484292/stem-cell-therapy-reduces-heart-failure-risk-by-57-following-heart-attack-in-phase-3-trial 2025-10-30T05:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/93ecd39cc0fa5388/clinical-evidence-supports-higher-somatostatin-analog-doses-for-progressive-neuroendocrine-tumors 2025-10-30T05:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/640c6de36cf553a8/italian-study-confirms-glp-1-drugs-enable-type-2-diabetes-remission-in-real-world-setting 2025-10-30T05:18:35+00:00 hourly 0.9 https://trial.medpath.com/news/256e8b75b727f55f/arkbio-launches-phase-ii-trial-of-ak0610-monoclonal-antibody-for-rsv-prevention-in-infants 2025-10-30T05:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/725b5794f2a426f5/european-biopharma-leaders-call-for-ai-driven-innovation-to-address-patent-cliff-and-funding-challenges 2025-10-30T03:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/932815faa51c36a8/uk-screening-committee-recommends-limited-prostate-cancer-screening-only-for-brca-carriers 2025-10-30T02:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/e1b8d233491d71bc/mayo-clinic-develops-novel-approach-to-enhance-cancer-immunotherapy-by-targeting-myeloid-cells 2025-10-30T01:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/c6a4722e063c6776/fda-issues-class-ii-recall-for-over-580000-bottles-of-prazosin-blood-pressure-medication-due-to-cancer-causing-impurities 2025-10-30T01:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/294e88efda023b64/risankizumab-shows-superior-efficacy-in-refractory-crohn-s-disease-patients-after-ustekinumab-failure 2025-10-30T01:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/6955f132eed6e0b0/novabridge-subsidiary-visara-assigns-vis-101-license-to-everest-medicines-for-asian-markets 2025-10-30T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/cc0b811305cfbb04/vaxil-bio-announces-350000-private-placement-as-former-immunotherapy-company-explores-strategic-pivot 2025-10-30T01:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/abe6e288f3847668/amneal-receives-fda-tentative-approval-for-generic-asthma-inhaler-targeting-329m-market 2025-10-30T01:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/3cafd28c85d5a39b/wave-life-sciences-reports-dose-dependent-activin-e-reductions-up-to-85-with-wve-007-in-obesity-trial 2025-10-30T01:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/e78c9099bc5bd46e/akebia-therapeutics-abandons-vafseo-expansion-trial-after-fda-disagreement-on-study-design 2025-10-29T21:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/3d053134570218b6/counterx-therapeutics-anti-fentanyl-antibody-ctrx-101-reverses-overdose-in-preclinical-study 2025-10-29T21:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/b7b563dab0b54779/researchers-identify-viral-entry-routes-and-develop-decoy-molecules-to-block-deadly-yellow-fever-and-tick-borne-encephalitis-viruses 2025-10-29T21:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/40e14569f4b8e223/anhorn-medicines-ai-designed-hair-loss-drug-ah-001-completes-phase-i-trial-with-excellent-safety-profile 2025-10-29T21:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/782b3d5e47635025/biostate-ai-partners-with-narayana-health-to-develop-first-ai-driven-cardiac-risk-models-for-indian-populations 2025-10-29T21:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/bdd8dc2a07a94526/ernexa-therapeutics-partners-with-cellipont-bioservices-to-advance-erna-101-cell-therapy-for-ovarian-cancer 2025-10-29T21:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/67a04d8bd4a993d3/fda-proposes-streamlined-biosimilar-approval-process-to-reduce-drug-costs-by-50 2025-10-29T21:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/3c9ff6e9b964b808/akston-launches-first-in-class-canine-cancer-immunotherapy-trial-using-novel-fc-fusion-platform 2025-10-29T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/71bd1a6735dc5ca4/aldeyra-therapeutics-pivots-to-next-generation-rasp-modulators-despite-phase-ii-success 2025-10-29T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/8236ef7da0cdb640/wheeler-bio-partners-with-mitsubishi-corporation-to-expand-ai-enabled-biomanufacturing-platform-across-asia-pacific 2025-10-29T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/ffa16131bad5d5b6/geneventiv-therapeutics-receives-fda-alignment-on-gene-therapy-development-plan-for-hemophilia-a 2025-10-29T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/5bc1fa37da86b494/tet2-clonal-hematopoiesis-identified-as-biomarker-for-enhanced-immunotherapy-response-in-large-scale-cancer-study 2025-10-29T17:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/d25fcdc1d1137a06/conavi-medical-secures-2-5m-cad-government-funding-to-advance-next-generation-cardiovascular-imaging-system 2025-10-29T17:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/e83350f36e815fac/polaritybio-secures-ama-cpt-codes-for-autologous-skin-construct-therapy-advancing-wound-healing-treatment-access 2025-10-29T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/e818338f28094fef/fda-proposes-streamlined-approval-pathway-to-accelerate-biosimilar-drug-development 2025-10-29T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/63df9d446efc2968/netramark-s-ai-platform-shows-promise-in-precision-psychiatry-with-enhanced-clinical-trial-design 2025-10-29T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/907b3c7bb55d591b/nyu-researchers-develop-novel-rage406r-compound-to-target-root-causes-of-diabetic-complications 2025-10-29T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/e1ec629df5ae1faa/immunotherapy-enhanced-total-neoadjuvant-therapy-shows-promise-for-organ-preservation-in-early-rectal-cancer 2025-10-29T17:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/3ad2d1140e36a318/glyconex-completes-patient-dosing-in-phase-3-trial-of-denosumab-biosimilar-spd8-for-osteoporosis 2025-10-29T17:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/ba532e6b4a4c2c56/johnson-johnson-launches-first-head-to-head-fcrn-blocker-study-in-myasthenia-gravis 2025-10-29T17:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/22d05f8bf70a60ae/pds-biotechnology-seeks-expedited-fda-approval-for-hpv16-positive-head-and-neck-cancer-immunotherapy 2025-10-29T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/fe90802490319b2e/healey-als-mymatch-program-advances-with-completion-of-first-trial-and-selection-of-tiziana-s-foralumab 2025-10-29T17:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/b221a1dc69977a3a/northwestern-scientists-develop-nanostructured-chemotherapy-with-20000x-enhanced-effectiveness-against-acute-myeloid-leukemia 2025-10-29T17:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/13a0bc14e6fc23ec/car-nk-cell-therapy-emerges-as-safer-alternative-to-car-t-cells-with-enhanced-manufacturing-advantages 2025-10-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d245f4a912c0ed0a/in8bio-adds-ohio-state-university-to-inb-100-gamma-delta-t-cell-therapy-trial-for-leukemia-patients 2025-10-29T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5a50b07739f4b2f/modex-therapeutics-and-regeneron-partner-on-1-billion-multispecific-antibody-collaboration 2025-10-29T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/cdd157acc1e23d04/medicus-pharma-partners-with-gorlin-syndrome-alliance-to-advance-compassionate-access-for-skinjecttm-microneedle-therapy 2025-10-29T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/4fddb0ed7d24b0fe/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-60mg-tablets-for-acute-coronary-syndrome 2025-10-29T13:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/1516005abd8ca9f8/relief-therapeutics-rlf-od032-achieves-bioequivalence-to-kuvan-in-pivotal-pku-study 2025-10-29T13:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/e7a9dd8d34c07db6/purdue-and-merck-develop-real-time-raman-spectroscopy-tool-for-vaccine-quality-control 2025-10-29T13:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/6376e9b444abb061/roche-receives-ce-mark-for-automated-dengue-diagnostic-test-amid-record-global-outbreak 2025-10-29T13:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/b3e2aac86765caa9/cepi-oxford-and-serum-institute-establish-100000-dose-nipah-virus-vaccine-reserve-for-emergency-response 2025-10-29T13:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/f159d5ffb4cba518/st-pharm-s-pirmitegravir-shows-first-clinical-proof-of-concept-for-novel-hiv-drug-class 2025-10-29T13:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/2f6c219cf477a44c/iaso-bio-partners-with-gc-cell-to-bring-first-fully-human-bcma-car-t-therapy-to-south-korea 2025-10-29T13:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/795776b0068fa409/atricure-initiates-boxx-noaf-trial-to-prevent-post-operative-atrial-fibrillation-in-cardiac-surgery-patients 2025-10-29T13:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/09339bf1268c9e38/ucb-presents-new-clinical-data-for-two-myasthenia-gravis-therapies-at-major-medical-conferences 2025-10-29T13:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/407d2aaaddf9e182/triceps-stroke-trial-reaches-200-patient-milestone-testing-non-invasive-vagus-nerve-stimulation-for-post-stroke-arm-weakness 2025-10-29T13:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/836ff2fa0e9e4cbe/world-first-breath-test-for-pancreatic-cancer-enters-large-scale-clinical-trial 2025-10-29T09:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/18c1c8c614931b72/yangli-pharmaceutical-raises-100-million-yuan-series-b-to-advance-anti-tumor-and-chronic-disease-pipeline 2025-10-29T09:23:11+00:00 hourly 0.9 https://trial.medpath.com/news/0f812bc5c21b7014/genfit-showcases-aclf-pipeline-advances-at-aasld-2025-with-three-novel-therapeutic-programs 2025-10-29T09:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/cfd9242980278adc/thermo-fisher-scientific-to-acquire-clinical-trial-data-firm-clario-for-10-billion 2025-10-29T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/d17e88ca94ae4771/labcorp-cuts-contract-research-growth-outlook-as-biotech-funding-crunch-persists 2025-10-29T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/79bb4269ef922b63/create-medicines-initiates-first-in-vivo-car-therapy-trial-in-frontline-gastroesophageal-cancer-treatment 2025-10-29T09:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/94cdfa62e1b643e2/sharon-trial-shows-promising-results-for-brca-mutated-pancreatic-cancer-using-stem-cell-transplant 2025-10-29T09:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/3f44efd4ead9ed0b/secretome-therapeutics-launches-phase-1-trial-of-stm-01-cell-therapy-for-dilated-cardiomyopathy 2025-10-29T09:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/fd6f037945c18ed4/locus-biosciences-partners-with-viatris-to-develop-engineered-bacteriophage-therapies-for-antibiotic-resistant-eye-infections 2025-10-29T05:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/af24da04ed030520/us-obesity-rate-drops-to-37-as-glp-1-weight-loss-drug-usage-more-than-doubles 2025-10-29T05:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/9533fd186dee8a81/oryzon-genomics-appoints-regulatory-expert-to-advance-vafidemstat-phase-iii-program-in-borderline-personality-disorder 2025-10-29T01:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/83f936258682ac30/orthopediatrics-secures-fda-approval-for-3p-small-mini-pediatric-plating-system 2025-10-29T01:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/3a6b81709881af69/nsw-government-invests-800000-to-expand-cancer-clinical-trial-access-in-rural-areas 2025-10-29T01:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/060d9d72baeca880/sunshine-biopharma-secures-health-canada-approval-for-domperidone-to-treat-cancer-related-nausea 2025-10-29T01:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/11050120b2324a18/medline-industries-files-for-ipo-targeting-5-billion-raise-in-largest-medical-supply-public-offering 2025-10-28T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/5bf2c40194e9b6b1/mayo-clinic-identifies-p95her2-protein-as-key-driver-of-resistance-to-trastuzumab-deruxtecan-in-her2-breast-cancer 2025-10-28T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3bfa6534d162d1d/enanta-s-edp-323-demonstrates-unprecedented-antiviral-activity-against-rsv-in-phase-iia-trial 2025-10-28T21:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/b3ffa3ee7b63cce5/in8bio-s-novel-gamma-delta-t-cell-engager-shows-promise-for-autoimmune-disease-treatment 2025-10-28T21:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/945afaa3e6777772/eli-lilly-partners-with-nvidia-to-build-pharma-s-most-powerful-ai-supercomputer-for-drug-discovery 2025-10-28T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/ac73d0a5d3a9193f/zag-bio-launches-with-80-million-to-pioneer-thymus-targeted-autoimmune-therapies 2025-10-28T17:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/6a5fc682d9241a42/harbour-biomed-launches-first-fully-human-generative-ai-hcab-model-to-accelerate-biologics-discovery 2025-10-28T17:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/5803d224ab429d6e/aytu-biopharma-secures-five-year-patent-extension-for-novel-depression-drug-exxua-through-2030 2025-10-28T17:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/c52ff3d2e60da9ef/rocket-science-health-secures-u-s-patent-for-precision-intranasal-drug-delivery-technology 2025-10-28T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/f8e629d51f49bb4e/modex-therapeutics-initiates-first-in-class-trispecific-antibody-trial-for-advanced-cancers 2025-10-28T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/a355c92b259791de/lumosa-therapeutics-lt3001-shows-promise-in-phase-2b-stroke-trial-with-extended-24-hour-treatment-window 2025-10-28T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/afeaeecaf6446d6a/merck-eisai-kidney-cancer-combination-shows-mixed-results-in-phase-3-trial 2025-10-28T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/ff43bf6264dbb0d8/yale-researchers-develop-dual-action-mrna-vaccine-for-aggressive-merkel-cell-carcinoma 2025-10-28T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/9a668efd97db7ccb/fda-approves-first-at-home-testing-for-non-hallucinogenic-psychedelic-like-depression-treatment 2025-10-28T17:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/f53ee3fe79fc065b/ema-grants-orphan-drug-designation-to-neurenati-s-neu-001-for-hirschsprung-disease-treatment 2025-10-28T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/e2405fc13d31f76e/exousia-pro-receives-fda-orphan-drug-designation-for-exosome-based-glioblastoma-treatment 2025-10-28T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/551a93df6116b32a/king-s-college-london-receives-ps2-7m-grant-to-develop-revolutionary-24-hour-nail-fungus-treatment-device 2025-10-28T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/9663e8a718bd110d/integral-molecular-s-membrane-proteome-array-nears-fda-qualification-as-first-nam-for-antibody-specificity-testing 2025-10-28T17:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/01ea3866adbe5555/milliporesigma-partners-with-promega-to-advance-3d-cell-culture-drug-discovery-technologies 2025-10-28T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/59c0db47444569e4/edesa-biotech-s-paridiprubart-shows-25-mortality-reduction-in-phase-3-ards-trial 2025-10-28T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/7f8108041d60e832/causeway-therapeutics-reports-positive-phase-2-results-for-tenomir-in-tennis-elbow-treatment 2025-10-28T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/f032ca10bf3bb1c3/two-novel-tumor-agnostic-trials-target-her2-positive-cancers-and-p53-mutations-at-esmo-2024 2025-10-28T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/cc8652307a45c3af/onl-therapeutics-initiates-phase-2-galaxy-trial-for-xelafaslatide-in-geographic-atrophy 2025-10-28T17:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/5e6986349d6e1fb6/novel-cell-death-pathways-transform-melanoma-immunotherapy-targeting-ferroptosis-pyroptosis-and-necroptosis 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c8acfa60e21d923/lipid-metabolism-emerges-as-key-target-for-cancer-immunotherapy-enhancement 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7eb50cd018461122/sequential-precision-therapy-achieves-79-month-survival-in-afp-producing-gastric-cancer-with-dynamic-her2-conversion 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1e1fb028a8f4116/osimertinib-shows-cost-effectiveness-in-china-but-not-us-for-stage-iii-egfr-mutant-nsclc-after-chemoradiotherapy 2025-10-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0621d6fcc7832b32/bat-suspends-vuse-one-vape-launch-as-fda-intensifies-regulatory-crackdown-on-unlicensed-products 2025-10-28T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/7a2997899613d9d2/domain-therapeutics-initiates-first-in-human-trial-of-dt-7012-anti-ccr8-antibody-for-advanced-solid-tumors 2025-10-28T13:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/beeac0dd75e100ab/south-africa-approves-groundbreaking-twice-yearly-hiv-prevention-injection-lenacapavir 2025-10-28T13:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/7d2c488426bfeae7/neom-and-wuxi-apptec-sign-strategic-partnership-to-establish-pharmaceutical-manufacturing-hub-in-saudi-arabia 2025-10-28T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/6cbe271d1cb5c495/fda-grants-breakthrough-device-designation-to-augurex-s-spinestat-test-for-axial-spondyloarthritis-diagnosis 2025-10-28T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/af1a046ebd2c9404/gsk-secures-745m-license-deal-for-novel-copd-sirna-therapy-receives-orphan-drug-status-for-cancer-adc 2025-10-28T13:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/fe741dbf458c305c/sudo-biosciences-reports-positive-phase-1-results-for-brain-penetrant-tyk2-inhibitor-sudo-550-in-neuroinflammatory-diseases 2025-10-28T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/579b77aa8d0b0ef8/organon-ceo-resigns-following-internal-investigation-into-nexplanon-sales-practices 2025-10-28T09:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/bb2ef9607b224397/novartis-reports-6-operating-income-growth-driven-by-new-drug-portfolio-performance 2025-10-28T09:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/4f3b0b0f3842a1f7/tubulis-secures-361m-series-c-to-advance-napi2b-targeting-adc-for-ovarian-cancer-and-lung-adenocarcinoma 2025-10-28T09:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/e7f2c705ef0d2734/japan-grants-orphan-designation-to-otl-200-gene-therapy-for-rare-childhood-disease-mld 2025-10-28T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/dbe9cc92ae26dd11/genentech-s-gazyva-shows-significant-efficacy-in-phase-iii-trial-for-pediatric-idiopathic-nephrotic-syndrome 2025-10-28T09:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/80ab67d4fee8e17b/coya-therapeutics-raises-23-million-to-advance-als-treatment-development 2025-10-28T09:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/f7866fb8b5fd2326/rmit-university-develops-molybdenum-oxide-nanodots-that-selectively-target-cancer-cells 2025-10-28T09:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/caabcac91e3e1995/wits-scientists-develop-breakthrough-nanomedicine-to-combat-drug-resistant-tb-in-heart-and-lungs 2025-10-28T09:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/14efd57ca9d6d869/kemwell-biopharma-s-bengaluru-facility-receives-fda-approval-for-commercial-biologics-manufacturing 2025-10-28T09:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/2f3eeab96882f82a/thermo-fisher-scientific-expands-bengaluru-r-d-center-with-160-crore-investment-to-advance-antibody-research 2025-10-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c4a325f2c2fb41f/elixir-medical-s-dynamx-bioadaptor-achieves-48-reduction-in-coronary-events-in-landmark-trial 2025-10-28T05:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/e864d47a67a33e46/myrio-therapeutics-forms-tri-party-alliance-with-penn-and-nyu-to-develop-next-generation-car-t-therapies-for-solid-tumors 2025-10-28T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/55538b1ddf54c32e/experimental-drug-ic7fc-shows-dual-promise-against-type-2-diabetes-and-heart-disease 2025-10-28T05:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/b4f8f703938c267a/onward-therapeutics-secures-worldwide-license-for-novel-onco-metabolism-program-ot-s00x 2025-10-28T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/8f24ce6e3c702c33/egfr-mutated-nsclc-pipeline-expands-with-30-therapies-as-fda-approves-dato-dxd-and-j-j-combination-shows-survival-benefit 2025-10-28T05:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/054474c2b89ede22/mit-study-shows-40hz-light-and-sound-therapy-slows-cognitive-decline-in-late-onset-alzheimer-s-disease 2025-10-28T01:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/38b1c8da6c3493df/fate-therapeutics-advances-two-phase-1-car-t-cell-therapy-studies-for-advanced-solid-tumors 2025-10-28T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/355ec2608aa5c782/mayo-clinic-and-bon-secours-lead-evangeline-trial-testing-z-endoxifen-for-premenopausal-breast-cancer 2025-10-28T01:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/4df6d537b1fa8ae5/biomarin-to-divest-roctavian-gene-therapy-following-commercial-struggles 2025-10-28T01:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/672230bdd3cc0810/fda-approves-simplified-single-injection-maintenance-regimen-for-lilly-s-omvoh-in-ulcerative-colitis 2025-10-28T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/1db0bab48d70ca64/fda-issues-final-guidance-on-patient-focused-clinical-outcome-assessments-for-drug-development 2025-10-28T01:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/4715dcab0f39de0c/robert-packard-center-and-als-united-launch-joint-research-initiative-to-target-tdp-43-pathways-in-als 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8fd8254da3e9a603/bristol-myers-squibb-exercises-2-2-billion-option-on-prothena-s-tau-targeting-alzheimer-s-antibody 2025-10-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a10318a04584a525/life-btk-trial-shows-durable-3-year-benefits-of-dissolving-scaffold-in-below-the-knee-clti 2025-10-27T23:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/dbd93784a774106b/amneal-launches-brekiya-first-self-administered-dhe-autoinjector-for-migraine-and-cluster-headaches 2025-10-27T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/44386f3e322e31c5/caribou-biosciences-to-present-first-clinical-data-from-dual-allogeneic-car-t-programs-in-lymphoma-and-multiple-myeloma 2025-10-27T21:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/7e13e3950e027fd8/adaptam-therapeutics-secures-eur3-million-to-develop-novel-cancer-immunotherapies-targeting-tumor-associated-myeloid-cells 2025-10-27T21:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/06f734003cde3c5f/major-pharmaceutical-companies-drive-2-7-billion-adc-investment-wave-in-2025 2025-10-27T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/c48e84e64b69a5c3/sylamorebio-secures-3-million-nih-grant-to-develop-blood-brain-barrier-therapy-for-rare-neurodegenerative-disease 2025-10-27T21:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/a06637d334288a19/nhs-trials-15-minute-blood-test-to-rapidly-diagnose-sepsis-and-meningitis-in-children 2025-10-27T21:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/32f50b010152eec2/partner-3-trial-shows-tavr-maintains-equivalent-outcomes-to-surgery-at-7-years-in-low-risk-patients 2025-10-27T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/e4f452ccd7dc9906/west-pharmaceutical-launches-synchrony-prefillable-syringe-system-to-streamline-biologics-delivery 2025-10-27T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/51e10f7eb88f004b/oric-pharmaceuticals-completes-dose-exploration-for-oric-944-in-prostate-cancer-shows-promising-efficacy-signals 2025-10-27T18:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/a7408b0642a09d2e/bempedoic-acid-monotherapy-reduces-cardiovascular-events-by-14-and-venous-thromboembolism-by-42-in-clear-outcomes-analysis 2025-10-27T18:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/cb02945012c10dc2/orchestra-biomed-initiates-pivotal-trial-for-novel-sirolimus-eluting-balloon-in-coronary-in-stent-restenosis 2025-10-27T18:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/957d672f64e33ff4/incyte-partners-with-enable-injections-to-develop-subcutaneous-delivery-system-for-first-in-class-mutcalr-therapy 2025-10-27T18:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/18390f562d4fb5c5/yorlabs-receives-fda-510-k-clearance-for-zero-capex-intracardiac-imaging-system 2025-10-27T18:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/2c582e7995fda03f/alphamab-oncology-s-jskn003-receives-fda-fast-track-designation-for-platinum-resistant-ovarian-cancer 2025-10-27T18:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/1e98237414531272/alphyn-secures-key-u-s-patent-for-atopic-dermatitis-drug-candidate-extending-ip-protection-to-2041 2025-10-27T18:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/9112d4e2b18f9ca8/wellgistics-health-partners-with-datavault-ai-to-develop-blockchain-enabled-pharmacychain-technology-for-639-billion-prescription-drug-market 2025-10-27T18:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/43bc4b58d8584c78/car-t-therapies-from-cabaletta-bio-and-bristol-myers-squibb-achieve-complete-remissions-in-severe-inflammatory-muscle-disease 2025-10-27T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/c9631efdaf9f587e/diakonos-oncology-s-doc1021-shows-promising-survival-signal-in-phase-1-pancreatic-cancer-trial 2025-10-27T18:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/5a63207283426357/neumora-therapeutics-initiates-phase-1-trial-for-second-m4-muscarinic-receptor-modulator-nmra-898 2025-10-27T18:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/06b2c739c7052239/sellas-life-sciences-secures-31-million-through-warrant-exercise-to-advance-cancer-therapeutics-pipeline 2025-10-27T18:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/89cf6d53fcae67d7/tolerance-bio-s-ipsc-derived-thymic-organoids-demonstrate-tumor-growth-inhibition-in-melanoma-model 2025-10-27T18:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/3a7b4a6ff48cf9a9/chromatin-bioscience-partners-with-purespring-therapeutics-to-develop-precision-gene-therapy-promoters-for-kidney-disease 2025-10-27T18:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/3bdf030f04cc58c5/bristol-myers-squibb-reports-sustained-efficacy-of-sotyktu-in-psoriatic-arthritis-and-lupus-through-extended-follow-up 2025-10-27T18:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/477f336b33286444/bahrain-partners-with-sandboxaq-in-1-billion-ai-driven-drug-discovery-initiative 2025-10-27T18:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/343e7529d6958a70/graymatter-robotics-secures-afwerx-contract-to-develop-ai-powered-robotic-system-for-aerospace-optical-component-manufacturing 2025-10-27T18:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/63c4bcea4dceb4ed/zenith-epigenetics-zen-3694-receives-fda-orphan-drug-designation-for-nut-carcinoma-treatment 2025-10-27T18:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/268e3f8099cdab93/guardant-health-partners-with-zephyr-ai-to-advance-cancer-biomarker-discovery-through-ai-driven-precision-medicine 2025-10-27T18:17:22+00:00 hourly 0.9 https://trial.medpath.com/news/a8d740e03dee15df/intellia-therapeutics-halts-phase-3-crispr-trials-after-patient-hospitalization-with-severe-liver-injury 2025-10-27T18:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/0022328adbaebab8/medera-advances-srd-001-gene-therapy-to-phase-2-trial-for-heart-failure-with-reduced-ejection-fraction 2025-10-27T13:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/ff8476360390470a/biorestorative-therapies-secures-japanese-patent-for-thermostem-r-cell-based-obesity-treatment-platform 2025-10-27T13:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/30775015c723fd8f/cohance-lifesciences-receives-oai-classification-from-fda-following-gmp-inspection-at-hyderabad-facility 2025-10-27T13:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/335d542726453179/daewoong-s-first-in-class-ipf-drug-bersiporocin-clears-third-safety-review-phase-2-trial-nears-completion 2025-10-27T13:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/b345b4d3d7788a7b/zenas-biopharma-s-obexelimab-achieves-95-reduction-in-brain-lesions-in-phase-2-multiple-sclerosis-trial 2025-10-27T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/48d2f40b03fa8c2a/shionogi-completes-acquisition-of-japan-tobacco-s-pharmaceutical-business-and-plans-manufacturing-subsidiary-merger 2025-10-27T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/c6fc25e0f642dfe4/cellcolabs-raises-12m-to-scale-mesenchymal-stem-cell-production-and-reduce-costs-by-90 2025-10-27T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/feba46391e15c9a2/nanoform-and-revio-therapeutics-partner-to-develop-gliora-a-novel-hydrogel-nanoformulation-for-high-grade-glioma-treatment 2025-10-27T13:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/069b9f9bdb4578df/evotec-receives-25m-milestone-payment-from-bristol-myers-squibb-for-neuroscience-partnership-progress 2025-10-27T13:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/13790d3499b3a893/bridgebio-reports-positive-phase-3-results-for-bbp-418-in-rare-muscular-dystrophy 2025-10-27T13:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/40e04f56073698c1/hemab-therapeutics-secures-157-million-series-c-to-advance-first-in-class-treatments-for-rare-bleeding-disorders 2025-10-27T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/f7f149d97911fef3/kazia-therapeutics-seeks-fda-meeting-for-paxalisib-conditional-approval-in-glioblastoma-under-project-frontrunner-initiative 2025-10-27T13:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/e0f289318d688349/stempeutics-licenses-stem-cell-therapy-stempeucel-to-japanese-partner-for-critical-limb-threatening-ischemia-treatment 2025-10-27T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/d1337c8aae3e13b9/gsk-acquires-exclusive-rights-to-syndivia-s-preclinical-adc-for-metastatic-castration-resistant-prostate-cancer 2025-10-27T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/f055f1e0bc7cca27/4basebio-s-synthetic-dna-platform-advances-to-phase-i-ii-clinical-trials-with-global-pharma-partner 2025-10-27T09:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/33051a6f2713eab4/raffles-medical-group-partners-with-gene-solutions-to-streamline-cancer-clinical-trial-access-in-southeast-asia 2025-10-27T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/04362a08d95646b2/adaptyx-biosciences-secures-14m-to-advance-multi-analyte-wearable-platform-for-continuous-molecular-monitoring 2025-10-27T05:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/f80aa5a90116765a/novartis-announces-12-billion-acquisition-of-avidity-biosciences-to-advance-rna-based-neuromuscular-therapeutics 2025-10-27T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/fff8fc12cf76ef60/xencor-reports-initial-phase-1-results-for-xmab819-enpp3-x-cd3-bispecific-in-clear-cell-renal-cell-carcinoma 2025-10-27T01:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/e4b3b0baebaf1bdc/real-world-data-confirms-safety-and-efficacy-of-transcatheter-tricuspid-valve-interventions 2025-10-27T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/016fa86d73b80449/medtronic-s-symplicity-renal-denervation-shows-sustained-18-mmhg-blood-pressure-reduction-at-three-years 2025-10-27T01:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/a54d59ff76ff07de/blood-based-test-shows-superior-early-lung-cancer-detection-compared-to-standard-ct-screening 2025-10-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d39011a0ebf67b0/inhibrx-biosciences-shares-surge-102-following-positive-phase-2-chondragon-trial-results-for-ozekibart-in-advanced-chondrosarcoma 2025-10-26T21:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/9862c7db47116acc/cristcot-s-novel-ulcerative-colitis-suppository-achieves-rapid-clinical-remission-in-phase-3-trial 2025-10-26T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/bab268a9dbae250f/novartis-pursues-12-billion-acquisition-of-avidity-biosciences 2025-10-26T21:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/9ff17242c7073ad6/phathom-pharmaceuticals-reports-positive-phase-3-results-for-voquezna-in-nocturnal-gerd-treatment 2025-10-26T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/44a4392cf0f675c4/glaukos-receives-fda-approval-for-epioxa-keratoconus-treatment-stock-surges-13-5 2025-10-26T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/349fd9e92a3164c4/ai-assisted-immune-profiling-reveals-novel-lymphocyte-signatures-in-soft-tissue-sarcoma 2025-10-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/259050d7482acff0/five-major-fda-decisions-expected-in-november-2025-across-cancer-rare-disease-and-genetic-disorders 2025-10-26T09:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/31d1f855ffd530e9/amprologix-advances-first-in-class-antibiotic-epidermicin-ni01-toward-human-trials 2025-10-26T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/c41ef08e31007f10/x4-pharmaceuticals-secures-135-million-to-advance-mavorixafor-phase-3-trials 2025-10-26T01:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/1fa5967811fda36e/oric-pharmaceuticals-advances-cancer-drug-pipeline-with-promising-prostate-cancer-data-and-major-pharma-partnerships 2025-10-25T21:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/850a3f9ea8db3ec9/voquezna-shows-rapid-relief-of-nighttime-gerd-symptoms-in-phase-3-trial 2025-10-25T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/42084a6831e7fce5/valthos-secures-30-million-to-develop-ai-powered-biodefense-platform-against-biological-threats 2025-10-25T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/528df27aaed959fb/astrazeneca-establishes-sixth-global-r-d-center-in-beijing-to-accelerate-ai-driven-drug-discovery 2025-10-25T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/61cb69ded878521f/bristol-myers-squibb-reports-promising-car-t-cell-therapy-results-for-three-autoimmune-diseases 2025-10-25T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/acefe4ba54d27291/quell-therapeutics-presents-promising-preclinical-data-for-qel-005-car-treg-therapy-at-acr-convergence-2025 2025-10-25T17:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/4d25c2472909268f/resmetirom-maintains-mash-efficacy-regardless-of-concurrent-diabetes-therapy-weight-loss-enhances-response 2025-10-25T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/9012cabb40ca2463/vera-therapeutics-advances-iga-nephropathy-treatment-with-positive-phase-3-origin-trial-results-and-fda-submission 2025-10-25T17:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/0c75430bff6e7aab/neuphoria-therapeutics-advances-bnc-210-phase-3-trial-for-social-anxiety-disorder 2025-10-25T13:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/43d5a1e4ecaf3f04/cardiovalve-submits-ce-mark-application-for-transcatheter-tricuspid-valve-replacement-system-following-successful-target-study 2025-10-25T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/a7dad3cb50463a74/fda-grants-first-emergency-use-authorization-for-lotilaner-to-treat-new-world-screwworm-in-dogs 2025-10-25T05:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/8833f53c75c7ce81/real-world-safety-analysis-reveals-new-adverse-events-associated-with-fenofibric-acid-for-hyperlipidemia-treatment 2025-10-25T01:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/c31f20fb862a1d8a/genenta-science-stock-surges-284-following-strategic-collaboration-with-anemocyte-for-gene-therapy-manufacturing 2025-10-25T01:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/4006a199c41b455a/nipocalimab-demonstrates-significant-efficacy-in-phase-2-sjogren-s-disease-trial-published-in-the-lancet 2025-10-25T01:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/382a322ce90e91fa/whitehawk-therapeutics-validates-ptk7-as-third-most-abundant-adc-target-across-157000-tumor-samples 2025-10-24T21:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/cec98f07b06db062/cogent-biosciences-unveils-promising-kras-inhibitor-data-with-superior-efficacy-profile 2025-10-24T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/e3c2ad3cd7c56c6e/fda-approves-javadin-oral-solution-for-hypertension-addressing-swallowing-difficulties-in-patient-care 2025-10-24T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/d1f72b5dc52b3ca0/omadacycline-shows-promise-in-phase-ii-trial-for-nontuberculous-mycobacterial-pulmonary-disease 2025-10-24T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/2db4f4b1b0605752/biogen-acquires-exclusive-rights-to-vanqua-bio-s-c5ar1-antagonist-for-inflammatory-diseases-in-1-06-billion-deal 2025-10-24T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/bc454b6ab0c1fab8/irish-consortium-secures-eur2-million-to-reduce-gene-therapy-manufacturing-costs 2025-10-24T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/4d16b9eb74d817b6/genenta-science-and-anemocyte-expand-partnership-to-commercialize-lentiviral-vector-plasmid-dna-technology-platform 2025-10-24T17:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/c56b90fecbcbf0e4/lilly-acquires-adverum-biotechnologies-for-262m-to-advance-gene-therapy-for-wet-amd 2025-10-24T17:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/f034daa6c283028a/dr-reddy-s-banks-on-semaglutide-denosumab-and-abatacept-to-counter-revlimid-revenue-decline 2025-10-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/859a7df4dc2faf4e/biogen-acquires-global-rights-to-vanqua-bio-s-inflammatory-disorder-drug-in-1-06-billion-deal 2025-10-24T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/2d650746fda152f2/giant-biogene-receives-nmpa-approval-for-first-recombinant-type-i-collagen-injectable-device 2025-10-24T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/da02601f8b470576/abivax-phase-iii-success-triggers-850-stock-surge-reignites-european-biotech-rally 2025-10-24T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/1032c2cb7eccf826/ventyx-biosciences-vtx3232-shows-78-reduction-in-key-inflammatory-marker-in-phase-ii-trial 2025-10-24T17:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/b24d8fc218d6228e/ac-immune-publishes-first-in-class-tdp-43-pet-tracer-data-in-nature-communications-advances-to-phase-1-trial 2025-10-24T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/815fdbb8a03ba9e1/ribo-receives-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-targeting-hepatitis-d-virus 2025-10-24T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/04cfffcd77013839/journey-medical-s-emrosi-demonstrates-superior-efficacy-over-oracea-in-phase-3-rosacea-trials 2025-10-24T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/229e91c642eaf373/neuraxis-receives-first-ever-fda-clearance-for-functional-dyspepsia-treatment-in-adults 2025-10-24T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/e4e5ebc8a7ae2685/chugai-pharmaceutical-acquires-renalys-pharma-for-98-million-to-expand-kidney-disease-portfolio 2025-10-24T17:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/8e712cd7a34f04aa/jacobio-pharmaceuticals-advances-pan-kras-inhibitor-jab-23e73-through-clinical-development 2025-10-24T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/a17836aff31241bd/abolis-biotechnologies-and-euroapi-partner-to-restore-european-corticosteroid-production-through-microbial-biotechnology 2025-10-24T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/fb7d69e5248df185/sobi-presents-new-clinical-data-for-rare-inflammatory-disease-treatments-at-acr-2025 2025-10-24T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/d9f61218e7a4bc44/curasen-therapeutics-initiates-phase-iia-trial-for-neurogenic-orthostatic-hypotension-treatment 2025-10-24T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/935495789b155fc6/cns-bridging-radiotherapy-shows-acceptable-safety-profile-prior-to-car-t-in-b-cell-lymphoma 2025-10-24T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/91aa14609739b667/neurobis-phase-ii-trial-launches-to-evaluate-cannabis-based-medicine-for-neurodegenerative-diseases 2025-10-24T09:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/3567c6506de5da7e/tlx250-cdx-shows-promise-in-triple-negative-breast-cancer-as-opalescence-trial-results-published 2025-10-24T05:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/af15eebe0e55686f/patient-advocacy-groups-launch-generic-cystic-fibrosis-drug-through-buyers-club-model 2025-10-24T05:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/a188a378102e2bcb/biodesix-expands-bio-rad-partnership-to-develop-advanced-esr1-mutation-testing-for-breast-cancer 2025-10-24T05:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/f1d1ac3197d48db7/bridgebio-oncology-s-bbo-11818-shows-promise-as-broad-spectrum-kras-inhibitor-in-preclinical-studies 2025-10-24T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/1a9c2e7967f9e60b/fda-issues-complete-response-letter-to-sydnexis-for-syd-101-pediatric-myopia-treatment 2025-10-24T01:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/54449887926b46bb/caredx-s-shore-study-validates-allosure-heart-as-reliable-biomarker-for-heart-transplant-rejection 2025-10-24T01:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/e5670693476f4b0b/pinetree-therapeutics-secures-47-million-series-b-to-advance-novel-protein-degraders-for-drug-resistant-cancers 2025-10-24T01:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/e7a5ea9b4b5b71c7/health-canada-approves-loqtorzi-as-first-immunotherapy-for-recurrent-nasopharyngeal-carcinoma 2025-10-24T01:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/95c19610b108e5f8/medicenna-to-present-updated-mdna11-clinical-data-at-esmo-immuno-oncology-congress-2025 2025-10-24T01:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/28b47264632d29b9/medivir-licenses-hdac-inhibitor-remetinostat-to-biossil-for-global-cancer-development 2025-10-24T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/dd2e83f36bd27aec/avava-receives-fda-clearance-for-wrinkle-treatment-using-focal-point-technology 2025-10-24T01:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/13a007dfbe4c4c53/fda-releases-three-guidance-documents-to-streamline-drug-development-and-reduce-application-returns 2025-10-24T01:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/5df8c78b6db1800c/terumo-s-opuswave-dual-sensor-imaging-system-receives-fda-510-k-clearance-for-coronary-artery-disease-treatment 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2770ae0bf87e71c/svf-vaccines-reports-promising-preclinical-results-for-svf-001-immunotherapy-in-chronic-hepatitis-b-and-d-coinfection 2025-10-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ac7c6262bf6da661/queen-mary-university-launches-procyon-diagnostics-to-commercialize-revolutionary-pancreatic-cancer-early-detection-test 2025-10-23T21:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/ead278338109941c/cerezentm-receives-european-approval-for-alzheimer-s-treatment-while-u-s-approval-remains-pending 2025-10-23T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/80c761ecfd7031a2/syngene-international-launches-oeb-5-gmp-bioconjugation-suite-to-accelerate-adc-development 2025-10-23T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/474d78b1bc647b87/vidac-pharma-to-explore-potential-collaboration-with-johnson-johnson-in-intratumoral-oncology 2025-10-23T21:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/8fcdac9a3ffeab9e/pritelivir-shows-superior-efficacy-over-foscarnet-in-phase-ii-trial-for-resistant-hsv-infections 2025-10-23T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/7c0f15a53e4dced3/pleopharma-raises-36m-series-b-to-advance-first-in-class-cannabis-withdrawal-treatment-to-phase-3 2025-10-23T21:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/505d6cc555238d01/major-leadership-transitions-reshape-pharmaceutical-industry-as-merck-kgaa-and-gsk-appoint-new-ceos 2025-10-23T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/b192c2ee0836b0b7/gilead-presents-three-year-livdelzi-data-showing-liver-health-stabilization-in-primary-biliary-cholangitis-patients 2025-10-23T21:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/737fba0c8ee0c713/fda-grants-fast-track-designation-to-novel-ultrasound-contrast-agent-asi-02-for-cardiac-imaging 2025-10-23T21:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/74aa13cc173f0a6b/clostrabio-launches-next-generation-probiotic-clb101-and-initiates-clinical-study-for-gut-health-applications 2025-10-23T21:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/1c25ec076fdd6312/silence-therapeutics-completes-enrollment-in-phase-2-trial-of-first-in-class-sirna-for-polycythemia-vera 2025-10-23T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/62473c841f07ed5e/ventyx-biosciences-vtx3232-shows-80-reduction-in-cardiovascular-inflammation-markers-in-phase-2-trial 2025-10-23T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/10fa3d39c582d1cd/eli-lilly-partners-with-cipla-to-expand-tirzepatide-access-in-india-through-dual-brand-strategy 2025-10-23T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/57261dcfd93330c1/china-s-nmpa-accepts-hansoh-pharmaceutical-s-ret-inhibitor-application-for-lung-cancer-treatment 2025-10-23T17:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/4e39be7dcb088b48/oramed-advances-oral-insulin-program-with-new-u-s-trial-following-subgroup-analysis 2025-10-23T17:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/9e39d30a2e5076ab/ginkgo-bioworks-partners-with-strm-bio-and-ubc-to-develop-in-vivo-car-therapies-for-autoimmune-diseases-under-arpa-h-program 2025-10-23T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/59da36fa9985312a/phenix-trial-demonstrates-sentinel-lymph-node-biopsy-alone-is-noninferior-to-full-lymphadenectomy-in-early-stage-cervical-cancer 2025-10-23T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d6e7942066deaa1/vial-initiates-phase-1-trial-of-novel-inhbe-sirna-therapy-for-obesity-treatment 2025-10-23T17:24:29+00:00 hourly 0.9 https://trial.medpath.com/news/bef5dd8ae27e4013/orion-secures-exclusive-license-for-abzena-s-cancer-targeting-monoclonal-antibody 2025-10-23T17:23:18+00:00 hourly 0.9 https://trial.medpath.com/news/775c7245a39b5c41/zeo-scientifix-poised-to-capitalize-on-florida-s-new-stem-cell-law-for-regenerative-medicine-market-expansion 2025-10-23T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/41137285ba5d7d75/biofrontera-inc-completes-11m-asset-acquisition-of-ameluz-and-rhodoled-us-rights 2025-10-23T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/ac0eaabede4a9a82/biotech-venture-funding-surges-70-9-in-q3-2025-signaling-market-recovery 2025-10-23T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/news/f12ca5be4ede4a23/george-medicines-gmrx2-demonstrates-significant-reduction-in-recurrent-stroke-risk-for-ich-survivors-in-trident-trial 2025-10-23T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/be6dcf833a170c2c/alloy-therapeutics-acquires-spannerwerks-to-expand-drug-development-capabilities 2025-10-23T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/dbf1d28a20edf7c6/protai-advances-ai-driven-drug-discovery-with-novel-tnfa-targeting-and-protein-degradation-technologies 2025-10-23T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/06a8bda700913d3e/kure-cells-secures-10m-to-revolutionize-car-t-manufacturing-with-same-day-platform 2025-10-23T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/f46b50b1dcb96c46/vantage-hemp-co-initiates-european-regulatory-filings-for-pharmaceutical-grade-cbd 2025-10-23T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/f391d31862a92813/hebrew-university-researchers-develop-ribotac-technology-to-target-cancer-linked-terra-rna 2025-10-23T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/db08ebc701f64348/heidelberg-pharma-s-hdp-101-adc-receives-fda-fast-track-designation-for-multiple-myeloma-treatment 2025-10-23T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/17c67521d379289d/nuvation-bio-initiates-phase-3-trial-of-safusidenib-for-high-grade-idh1-mutant-glioma-maintenance-treatment 2025-10-23T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/fe4967c34e5172f9/new-drug-launch-prices-rise-51-despite-inflation-adjustments-icer-analysis-reveals 2025-10-23T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/da6283bdf1282151/roche-shares-drop-2-8-as-vabysmo-and-hemlibra-sales-miss-expectations-despite-revenue-growth 2025-10-23T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/21902c1cf3bc19d5/moderna-s-mrna-1345-rsv-vaccine-shows-safety-and-efficacy-in-solid-organ-transplant-recipients 2025-10-23T13:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/2d722b2be939a8dc/agc-biologics-partners-with-rarity-pbc-to-advance-first-commercial-gene-therapy-for-ada-scid-bubble-baby-disease 2025-10-23T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/815a0418c31be6e5/mgi-tech-and-eva-holding-group-partner-to-bring-first-ivd-certified-high-throughput-genetic-sequencer-to-brazil 2025-10-23T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/16538da35bb2e1f8/pazopanib-shows-promising-results-in-treating-children-with-multi-metastatic-ewing-sarcoma 2025-10-23T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/7f9d8c41f63eadd5/glenmark-to-launch-generic-ropivacaine-anesthesia-drug-in-us-market 2025-10-23T13:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/e52f1bfbd49adbf6/thx-pharma-raises-eur8-million-to-advance-rare-neurological-disease-treatments 2025-10-23T09:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/cd8c81f11b1ef195/fda-recalls-141984-bottles-of-generic-atorvastatin-due-to-failed-dissolution-standards 2025-10-23T09:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/87c3579d48495708/biocon-biologics-receives-health-canada-approval-for-ustekinumab-biosimilar-yesintek 2025-10-23T09:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/43fba0e578806121/sanofi-expands-decade-long-partnership-with-medidata-to-accelerate-clinical-trial-development 2025-10-23T09:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/e441e841b7b72e6e/accent-therapeutics-unveils-promising-preclinical-data-for-novel-cancer-therapies-atx-295-and-atx-559-at-major-oncology-conference 2025-10-23T05:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/d6bd009c4efbf16f/hutchmed-unveils-first-in-class-hmpl-a251-antibody-targeted-therapy-conjugate-with-superior-efficacy-against-her2-positive-cancers 2025-10-23T05:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/402cbafaf8e7a637/first-human-trial-demonstrates-safety-of-rectal-oxygen-delivery-for-respiratory-support 2025-10-23T05:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/0ba7c744deb2df6e/xcellon-biologics-expands-adc-development-capabilities-through-strategic-partnerships-with-invenra-and-intocell 2025-10-23T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/842b53c8fc40b45b/gene-expression-test-reduces-need-for-invasive-lymph-node-biopsies-in-early-stage-melanoma-patients 2025-10-23T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/c507d34d17dc58f1/aptis-expands-adc-platform-through-strategic-partnerships-for-next-generation-cancer-therapeutics 2025-10-23T01:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/435bf650eb672b90/delaware-court-blocks-ingenus-from-pursuing-cancer-drug-patent-claims-after-prior-invalidation 2025-10-23T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/c002946bc9bf74d6/real-world-study-shows-pazopanib-outperforms-sunitinib-in-advanced-alveolar-soft-part-sarcoma 2025-10-23T01:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/2182a11d67f89e34/moderna-discontinues-cmv-vaccine-development-after-phase-3-trial-fails-to-meet-primary-endpoint 2025-10-23T01:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/2a56cc0720aead72/inhibrx-to-present-topline-results-from-registrational-chondrosarcoma-trial-of-ozekibart 2025-10-23T01:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/3b78d47a06c73c70/swallowable-bioluminescent-capsule-shows-promise-for-early-detection-of-life-threatening-intestinal-blood-flow-disorder 2025-10-22T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/51deed24f7a15df2/avadel-and-jazz-pharmaceuticals-settle-90-million-narcolepsy-drug-dispute-over-lumryz 2025-10-22T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/8edda5aca143f0c8/cyncado-therapeutics-presents-first-evidence-of-a2b-receptor-inhibition-s-direct-anti-tumor-effects-in-mesothelioma 2025-10-22T21:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/d622b094fc33c926/arcturus-therapeutics-inhaled-mrna-therapy-arct-032-shows-mixed-results-in-phase-2-cystic-fibrosis-trial 2025-10-22T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/6ae8d7aebc1a83bd/university-of-louisville-receives-11-5-million-nih-grant-to-advance-cancer-immunotherapy-research-and-training 2025-10-22T21:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/3c895ef19a1455a5/basking-biosciences-advances-phase-2-stroke-trial-with-new-ceo-appointment-and-27-5m-funding 2025-10-22T21:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/199c99ed5b84eab0/zenocutuzumab-shows-37-response-rate-in-rare-nrg1-positive-cholangiocarcinoma 2025-10-22T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/1964470af000c34c/alkermes-acquires-avadel-for-up-to-2-1b-to-accelerate-sleep-medicine-market-entry 2025-10-22T21:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/2c911523716158ef/biokin-receives-record-250-million-adc-milestone-payment-from-bristol-myers-squibb 2025-10-22T21:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/e2209c0ef24b6569/gempharmatech-partners-with-memorial-sloan-kettering-to-accelerate-fully-human-antibody-discovery-for-cancer-therapy 2025-10-22T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/a02e12d397259ea4/ensifentrine-demonstrates-sustained-improvement-in-copd-symptoms-and-quality-of-life-in-stable-patients 2025-10-22T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/2a3d793453edc9c8/first-in-class-fcrn-inhibitor-prevents-congenital-heart-block-in-high-risk-pregnancy 2025-10-22T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/7ccaa1b287ba2ed4/metis-techbio-s-ai-designed-drug-mts-004-becomes-first-in-china-to-complete-phase-iii-trial-for-pseudobulbar-affect 2025-10-22T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/9b6811b2b82e6f3d/medherant-s-testosterone-patch-shows-promise-in-phase-1-trial-for-menopausal-women 2025-10-22T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/378d9da1688f0a5a/breast-cancer-r-d-pipeline-expands-to-over-300-drugs-with-novel-protacs-adcs-and-cdk-inhibitors 2025-10-22T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/70036963d6472e1e/addenbrooke-s-hospital-becomes-first-in-europe-to-deliver-histotripsy-cancer-treatment-outside-clinical-trials 2025-10-22T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/d713c2ecb787236c/global-registry-data-confirms-survival-advantage-of-mogamulizumab-in-advanced-cutaneous-t-cell-lymphoma 2025-10-22T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/ea7c17be207f311d/adarx-pharmaceuticals-initiates-phase-3-trial-for-adx-324-in-hereditary-angioedema-receives-fda-orphan-drug-designation 2025-10-22T17:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/6fbc9e606f4a1ba4/sironax-strengthens-leadership-team-with-two-senior-appointments-to-advance-age-related-disease-pipeline 2025-10-22T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/ca4fa27332c0a041/symrise-invests-in-cellibre-to-advance-precision-fermentation-technology-for-flavor-and-cosmetic-ingredients 2025-10-22T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/0cf9cfabfd9c4d62/electra-therapeutics-ela026-receives-fda-breakthrough-therapy-and-ema-priority-designations-for-rare-inflammatory-disease 2025-10-22T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/9efb9e928356826d/gammatile-reduces-brain-metastases-recurrence-risk-by-over-50-in-phase-3-roads-trial 2025-10-22T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/14ca99738049c597/solenic-medical-s-alternating-magnetic-field-technology-shows-promise-in-fda-authorized-compassionate-use-for-prosthetic-joint-infection 2025-10-22T17:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/dddd615e10bff2f5/partitionbio-wins-elrig-innovation-award-for-peptide-based-cell-delivery-platform 2025-10-22T17:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/86ccccf2bee42ba8/fda-approves-first-drug-under-new-priority-voucher-program-fast-tracking-augmentin-xr-to-strengthen-us-manufacturing 2025-10-22T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/028825b19d88b953/oncohost-expands-prophetnsclc-r-precision-oncology-test-nationwide-with-new-york-state-laboratory-permit 2025-10-22T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/6834396fc367a515/nigeria-launches-first-immunotherapy-program-for-colorectal-cancer-in-sub-saharan-africa 2025-10-22T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/cb20617323c73d89/large-scale-pharmacovigilance-study-reveals-distinct-infection-risk-profiles-among-immune-checkpoint-inhibitors 2025-10-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/95bc5426948bf060/private-equity-consortium-lowers-acceptance-threshold-for-bavarian-nordic-takeover-amid-shareholder-opposition 2025-10-22T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/fec06fff70a4d4d8/tonix-pharmaceuticals-initiates-first-in-human-study-of-intranasal-oxytocin-for-rare-endocrine-disorder 2025-10-22T13:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/c7c22af68ba05786/breakthrough-urine-test-could-replace-invasive-kidney-biopsies-for-lupus-nephritis-monitoring 2025-10-22T13:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/7913de34153ce6e2/smartbax-secures-eur4-7m-to-advance-novel-antibiotic-compounds-against-multi-drug-resistant-bacteria 2025-10-22T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/4df93aac70c978b7/elevara-medicines-secures-70-million-series-a-to-advance-novel-cdk4-6-inhibitor-for-rheumatoid-arthritis 2025-10-22T13:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/d577346fca38a22a/mhra-launches-ps2m-ai-initiative-to-predict-drug-interactions-and-accelerate-medicine-approvals 2025-10-22T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/dc0f93fe649148fb/alvotech-restructures-leadership-team-with-new-commercial-operations-appointments 2025-10-22T13:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/c9a1a612223dc156/flagship-pioneering-launches-expedition-medicines-with-50m-investment-in-ai-driven-covalent-drug-discovery 2025-10-22T13:17:02+00:00 hourly 0.9 https://trial.medpath.com/news/04ed6ad3c52d29e1/ena-respiratory-raises-22-4m-to-advance-inna-051-nasal-spray-in-phase-ii-trial-for-respiratory-virus-prevention 2025-10-22T13:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/db0837cafbd8a1f8/gsk-s-next-generation-low-carbon-ventolin-inhaler-shows-therapeutic-equivalence-in-phase-iii-trial 2025-10-22T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/a90c8122b13d2329/novartis-cosentyx-achieves-primary-and-secondary-endpoints-in-phase-iii-polymyalgia-rheumatica-trial 2025-10-22T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/bcedf3b4e3617b25/sanofi-s-efdoralprin-alfa-achieves-primary-endpoints-in-phase-2-alpha-1-antitrypsin-deficiency-study 2025-10-22T09:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/4611305fddb8fba2/ipsen-acquires-imcheck-therapeutics-for-eur1-billion-to-advance-novel-aml-immunotherapy 2025-10-22T09:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/342bbe647c0c5c76/fda-finds-egregious-manufacturing-violations-at-nephron-pharmaceuticals-despite-years-of-warnings 2025-10-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/48da129f5da9b11f/revium-rx-advances-nano-mupirocin-toward-phase-1-trials-to-combat-antibiotic-resistant-infections 2025-10-22T05:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/ac15a2804b61f4ea/india-proposes-regulatory-framework-for-cell-and-gene-therapy-manufacturing-licenses 2025-10-22T05:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/4067ab29005e652c/takeda-and-innovent-biologics-form-11-4-billion-strategic-partnership-to-advance-next-generation-cancer-therapies 2025-10-22T05:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/4821e3144f0d3af3/early-oncology-data-becomes-critical-driver-of-investment-as-pharma-funding-contracts 2025-10-22T03:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/1fb4d3e1f8dc2ec9/inovio-s-dna-encoded-antibody-platform-achieves-72-week-sustained-expression-in-phase-1-trial 2025-10-22T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/9b6da5a0a2d666b7/shuttle-pharmaceuticals-signs-10m-loi-to-acquire-ai-platform-molecule-ai-to-enhance-radiation-therapy-development 2025-10-22T01:22:35+00:00 hourly 0.9 https://trial.medpath.com/news/d78f04d7f7c07d72/chemify-secures-50-million-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-10-22T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/668ca5b91dc685a9/selection-s-si-544-demonstrates-disease-modifying-potential-in-phase-1b-psoriasis-trial 2025-10-22T01:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/ab2008c733be1539/french-cultivated-meat-companies-gourmey-and-vital-meat-merge-to-form-parima-creating-global-leader-in-cell-based-animal-production 2025-10-22T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/9f22779bbd04a83a/oracle-and-baylor-college-of-medicine-launch-major-ai-driven-research-initiative-to-combat-rising-alcohol-related-liver-disease 2025-10-22T01:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/01c0a79cf5c6bfa1/alector-s-latozinemab-fails-phase-iii-trial-for-frontotemporal-dementia-company-cuts-workforce-by-half 2025-10-22T01:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/2144cec48720cbbb/trivarx-completes-recruitment-for-60-patient-veterans-mental-health-trial-using-novel-ecg-algorithm 2025-10-22T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/f4eb9af12866ff2e/pharmajet-expands-needle-free-technology-portfolio-with-self-injection-pen-development 2025-10-21T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/751d20cec88fde0a/light-chain-bioscience-reports-promising-survival-data-for-ni-1801-bispecific-antibody-in-platinum-resistant-ovarian-cancer 2025-10-21T21:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/ee0ad12c04ba670c/university-of-galway-researchers-discover-sugar-coating-mechanism-that-helps-bowel-cancer-evade-immune-system 2025-10-21T21:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/bc3a82e57715d00d/hengrui-s-perioperative-immunotherapy-combo-achieves-breakthrough-in-hepatocellular-carcinoma-treatment 2025-10-21T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/15bdf95f5801f10f/medibeacon-s-transdermal-gfr-system-receives-china-approval-opening-major-market-for-point-of-care-kidney-function-testing 2025-10-21T21:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/a8e874d7a23dd912/dermatology-clinical-trials-evolve-to-meet-rising-efficacy-standards-and-biologic-innovation 2025-10-21T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/19c6c93069753167/theraclion-s-sonovein-r-hifu-platform-achieves-key-chinese-safety-certification-advancing-toward-nmpa-market-authorization 2025-10-21T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/f23b7816d9bcef76/indian-phase-iii-trial-shows-carboplatin-benefits-premenopausal-triple-negative-breast-cancer-patients 2025-10-21T21:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/dd2ffdf350f8dbfe/pranax-s-licensed-exosome-manufacturing-technology-demonstrates-safety-in-phase-i-pancreatic-cancer-trial 2025-10-21T21:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/83dc051c086c6335/merck-kgaa-s-precem-tct-adc-shows-31-response-rate-in-colorectal-cancer-advances-to-phase-iii 2025-10-21T21:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/b12e90f7dcdcac2a/bptf-protein-emerges-as-key-target-to-overcome-hormone-therapy-resistance-in-er-breast-cancer 2025-10-21T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/8fb7880542aefd5e/onkos-surgical-receives-fda-510-k-clearance-for-eleos-proximal-tibia-with-nanocept-antibacterial-technology 2025-10-21T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/0fa22b5cf859e07e/curia-s-burlington-sterile-manufacturing-facility-wins-massachusetts-manufacturer-of-the-year-award 2025-10-21T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/1950988743b279f0/pacira-biosciences-faces-generic-competition-as-two-companies-file-abbreviated-new-drug-applications-for-exparel 2025-10-21T17:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/41c0eb4509d7ae8b/fda-grants-fast-track-and-orphan-drug-designations-to-nbm-bmx-for-metastatic-uveal-melanoma 2025-10-21T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/c88ebc3f0ddadf5a/pacira-biosciences-faces-generic-challenge-as-whiteoak-files-anda-for-exparel 2025-10-21T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/5dd1b1f030c17262/simcha-therapeutics-reports-enhanced-cancer-treatment-efficacy-with-decoy-resistant-il-18-and-bispecific-t-cell-engagers 2025-10-21T17:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/11986544e418a17b/fda-approves-subcutaneous-pembrolizumab-for-solid-tumors-transforming-bladder-cancer-treatment-delivery 2025-10-21T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/4866a08713eacf2c/lundbeck-partners-with-contera-pharma-to-develop-rna-targeting-oligonucleotide-therapies-for-neurological-disorders 2025-10-21T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/8ed4981edc551811/phase-3-buran-trial-shows-buparlisib-paclitaxel-combination-fails-to-improve-survival-in-pd-1-refractory-head-and-neck-cancer 2025-10-21T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/8be7d4e752dbda17/gld-partners-acquires-seelos-therapeutics-assets-advancing-ketamine-and-trehalose-programs-to-phase-3-trials 2025-10-21T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/11ed836fe679fab8/quoin-pharmaceuticals-receives-fda-orphan-drug-designation-for-qrx003-in-netherton-syndrome-treatment 2025-10-21T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/747b5b00b6c05eb9/bayer-s-asundexian-meets-primary-endpoints-in-phase-iii-oceanic-stroke-trial-for-secondary-stroke-prevention 2025-10-21T17:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/2aeed4c1529947dc/durvalumab-shows-clinical-promise-but-faces-cost-effectiveness-hurdles-in-china-s-small-cell-lung-cancer-treatment 2025-10-21T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/b47ba079bc52bf75/ventus-therapeutics-partners-with-genentech-in-460m-ai-driven-drug-discovery-collaboration 2025-10-21T17:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/0711f34cbb0bbcca/fda-reports-death-in-patient-treated-with-ascendis-pharma-s-yorvipath-raising-safety-questions 2025-10-21T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/3525aaf01dc78bed/tenon-medical-receives-fda-510-k-clearance-for-simmetry-si-joint-fusion-system 2025-10-21T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/d29a6d3c41e0a9c8/fda-approves-roche-s-gazyva-for-lupus-nephritis-treatment-expanding-therapeutic-options 2025-10-21T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/e2c174197ad899b4/caremetx-and-syneos-health-form-strategic-partnership-to-accelerate-specialty-medication-access 2025-10-21T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/6d4c7231ca36731f/precision-immunomodulation-emerges-as-key-strategy-to-balance-inflammation-and-restore-tissue-homeostasis 2025-10-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be2e13d95cfa3d28/eleva-s-cpv-104-advances-to-phase-1b-testing-in-c3g-patients-after-successful-safety-evaluation 2025-10-21T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/959c9d9cf9552f40/ibio-to-present-preclinical-data-on-first-in-class-activin-e-antibody-ibio-610-for-obesity-treatment 2025-10-21T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/8cd767a2c093e6e9/glp-1-drugs-show-enhanced-mortality-benefits-in-type-2-diabetes-patients-with-sleep-apnea 2025-10-21T13:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/08f60f8e5b7aa99e/breakthrough-epigenetic-editing-platform-enables-safe-multi-gene-modification-in-car-t-cells 2025-10-21T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/d40283a2eae662ff/vcn-01-oncolytic-virus-shows-promising-survival-benefits-in-metastatic-pancreatic-cancer-trial 2025-10-21T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/1f0b34f375041bb4/iaso-bio-receives-japanese-regulatory-approval-for-bcma-car-t-clinical-trial 2025-10-21T13:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/5486417ea245c007/bovine-tb-cattle-vaccine-field-trials-advance-to-phase-3-with-750-animals-across-uk-farms 2025-10-21T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/6226729a0cd9e626/hanchorbio-s-hcb101-shows-promising-safety-profile-and-early-efficacy-in-phase-1-cancer-trial 2025-10-21T13:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/93cdc6ca55d7b02c/gondolabio-s-port-77-receives-fda-orphan-drug-and-fast-track-designations-for-rare-protoporphyria-treatment 2025-10-21T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/b3a108a40c021dca/ferrer-completes-early-enrollment-for-phase-ii-psp-trial-testing-novel-oga-inhibitor-fnp-223 2025-10-21T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/abda086193256309/crisproff-epigenetic-editing-enables-durable-gene-silencing-in-car-t-cell-therapy 2025-10-21T13:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/32c5d2ac1445f1c2/samsung-bioepis-partners-with-phrontline-to-develop-next-generation-dual-payload-adcs-for-cancer-treatment 2025-10-21T09:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/4d688c7753af7157/europe-s-first-ranibizumab-biosimilar-pre-filled-syringe-launches-in-france 2025-10-21T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/002abaa747bde585/sk-biopharmaceuticals-and-eurofarma-launch-ai-powered-epilepsy-management-joint-venture 2025-10-21T09:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/8db3f1550a3d3160/incyte-presents-early-clinical-data-for-novel-oncology-therapies-at-esmo-congress-2025 2025-10-21T09:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/93b1eb3af8856806/phase-2-trial-shows-70-response-rate-for-novel-combination-therapy-in-advanced-neuroendocrine-tumors 2025-10-21T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/a72a1e1a33e716af/solaria-bio-s-bondiatm-demonstrates-85-improvement-in-bone-density-through-novel-gut-bone-axis-targeting 2025-10-21T05:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/0abb0d687da0b4d8/fda-clears-lirum-s-lx-101-for-inclusion-in-rapid-platform-trial-for-rare-pediatric-cancers 2025-10-21T01:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/9975d3437701571b/camrelizumab-famitinib-combination-demonstrates-superior-survival-outcomes-in-metastatic-cervical-cancer 2025-10-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/1b46fa8a63095879/fda-approves-tirzepatide-for-obstructive-sleep-apnea-expanding-glp-1-therapy-access-beyond-diabetes 2025-10-21T01:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/d80b80d752d4baeb/pacira-biosciences-reports-3-year-sustained-efficacy-data-for-pcrx-201-gene-therapy-in-knee-osteoarthritis 2025-10-21T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/7ab7aa696a6066db/teva-partners-with-prestige-biopharma-to-commercialize-tuznue-trastuzumab-biosimilar-across-europe 2025-10-21T01:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/5971d3c880f526de/rwanda-fda-approves-first-biosimilar-ranibizumab-in-africa-for-sight-threatening-eye-diseases 2025-10-21T01:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/4bf4bb27edbfcc11/verrica-pharmaceuticals-receives-ema-support-for-ycanth-european-approval-without-additional-phase-3-studies 2025-10-21T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/b2bafb4f8c635bb4/technology-partnership-announcement-knectiq-and-src-uk-licensing-agreement-for-defense-intelligence-platforms 2025-10-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a64d408a5bb4ff1d/avance-clinical-establishes-early-phase-center-of-excellence-to-streamline-biotech-clinical-development 2025-10-20T22:00:35+00:00 hourly 0.9 https://trial.medpath.com/news/bd105c3ea7c5a555/judo-bio-demonstrates-sustained-kidney-selective-gene-silencing-with-megalin-striker-platform-across-species 2025-10-20T21:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/41fe23fa347c97df/fda-drug-approval-rates-drop-to-73-as-review-delays-and-rejections-rise-in-q3 2025-10-20T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/4aa7eaa53db9fbfb/faeth-therapeutics-raises-25m-to-advance-piktor-therapy-after-80-response-rate-in-endometrial-cancer 2025-10-20T21:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/34dd7ed1a3014cbc/sona-nanotech-s-targeted-hyperthermia-therapy-shows-80-response-rate-in-first-in-human-melanoma-study 2025-10-20T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/7883ae263bd42181/tigit-checkpoint-inhibitor-discovered-to-promote-tissue-healing-beyond-cancer-treatment 2025-10-20T21:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/54178ffd6024cee0/bemarituzumab-plus-chemotherapy-shows-initial-overall-survival-benefit-in-fgfr2b-positive-gastric-cancer 2025-10-20T21:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/afdf3ddb0228713f/chinese-adc-companies-showcase-breakthrough-clinical-data-at-esmo-2025 2025-10-20T21:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/90c5503437c54d65/camrelizumab-famitinib-combination-shows-superior-survival-outcomes-in-phase-iii-cervical-cancer-trial 2025-10-20T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/a88ad53d0cd39d96/stoke-therapeutics-reveals-two-year-natural-history-data-for-rare-eye-disease-adoa-supporting-phase-1-trial-of-stk-002 2025-10-20T21:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/3266afcd37f30409/cytomx-therapeutics-appoints-rachael-lester-as-chief-business-officer-to-advance-probody-platform 2025-10-20T20:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e2ab7de99a5d0f7/prolong-pharmaceuticals-reports-promising-phase-1-2-results-for-pp-007-in-acute-ischemic-stroke 2025-10-20T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/3ea2b8b0c2012759/shionogi-s-cefiderocol-shows-superior-outcomes-when-used-as-early-treatment-for-drug-resistant-infections 2025-10-20T17:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/931e0e4c16079a4e/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-refractory-autoimmune-diseases-in-first-in-human-trial 2025-10-20T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/bf641597ee2a2fa0/sunshine-biopharma-launches-generic-doxycycline-in-canada-targeting-growing-antibiotic-market 2025-10-20T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/9b3f74578b290303/glyconex-advances-novel-glycan-targeted-adc-gnx1021-for-her2-low-gastric-cancer 2025-10-20T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/627d17b851a847ef/university-of-pennsylvania-scientists-achieve-breakthrough-results-in-early-car-t-cell-therapy-trials-leading-to-kymriah-development 2025-10-20T17:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/570d31090231aa45/genflow-biosciences-advances-patent-protection-for-longevity-gene-therapy-platform 2025-10-20T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/2043dfbdb3dc552a/rinvoq-demonstrates-superior-efficacy-over-humira-in-first-head-to-head-trial-for-tnf-inhibitor-experienced-rheumatoid-arthritis-patients 2025-10-20T17:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/63438caab2f473ea/abeona-therapeutics-appoints-gene-therapy-expert-james-gow-as-senior-vp-of-clinical-development 2025-10-20T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/3506817e3f1cd0e4/adarx-pharmaceuticals-to-present-phase-1-data-for-adx-038-sirna-therapy-at-asn-kidney-week-2025 2025-10-20T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/948d3309ee08bac6/rapt-therapeutics-rpt904-shows-comparable-efficacy-to-xolair-in-chronic-hives-trial 2025-10-20T17:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/820683d3d8634613/valink-therapeutics-raises-11-8-million-to-advance-bispecific-adc-platform-for-cancer-treatment 2025-10-20T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/e71c1be28c1ee241/the-jackson-laboratory-acquires-new-york-stem-cell-foundation-to-accelerate-precision-medicine-discovery 2025-10-20T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/9de4c40878493ff5/charles-river-laboratories-partners-with-x-chem-to-expand-hit-identification-capabilities-through-dna-encoded-library-technology 2025-10-20T17:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/61d07aa22a3b675c/cumberland-pharmaceuticals-partners-with-redhill-to-co-commercialize-h-pylori-treatment-talicia 2025-10-20T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/be674aceb23c4320/ogrd-alliance-expands-phospholipoproteomic-platform-across-asia-and-mena-regions 2025-10-20T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/556cdd2339004741/proqr-receives-ema-authorization-to-begin-phase-1-trial-of-ax-0810-rna-editing-therapy-for-cholestatic-diseases 2025-10-20T17:24:19+00:00 hourly 0.9 https://trial.medpath.com/news/d58e6554dbac09ae/endo-launches-first-generic-version-of-ravicti-for-rare-urea-cycle-disorders 2025-10-20T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/88f0722abb43ae67/citius-oncology-completes-distribution-network-for-lymphir-with-mckesson-partnership-ahead-of-q4-2025-launch 2025-10-20T17:23:05+00:00 hourly 0.9 https://trial.medpath.com/news/24443909f576446a/oura-pursues-fda-clearance-for-blood-pressure-monitoring-feature-in-smart-ring 2025-10-20T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/d432c4cc54f6d3be/first-health-canada-approved-phase-2-trial-investigates-psilocybin-microdosing-for-generalized-anxiety-disorder 2025-10-20T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/b1abbcaa616e0fbf/exelixis-zanzalintinib-combination-shows-modest-survival-benefit-in-advanced-colorectal-cancer-trial 2025-10-20T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/3ffafb8472ea8a31/ibd-patients-face-elevated-risk-of-depression-and-anxiety-through-gut-brain-axis-dysfunction 2025-10-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f51c165c1a206e07/sunrock-biopharma-partners-with-chime-biologics-to-advance-anti-ccr9-antibody-srb5-for-inflammatory-bowel-disease 2025-10-20T13:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/88ce5ea3a8c1b938/weightwatchers-partners-with-amazon-pharmacy-to-expand-glp-1-obesity-treatment-access 2025-10-20T13:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/e593904420eb513a/unc-scientists-engineer-dna-flower-robots-for-targeted-drug-delivery 2025-10-20T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/ccd2ad91c3a4b2b8/autolus-therapeutics-initiates-first-in-human-car-t-trial-for-progressive-multiple-sclerosis 2025-10-20T13:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/a58bb915a63bd7f9/uc-san-diego-researchers-overcome-aml-drug-resistance-with-novel-combination-therapy 2025-10-20T13:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/3b99c724a5c12bb6/stratifai-partners-with-memorial-sloan-kettering-to-validate-ai-powered-breast-cancer-biomarker-platform 2025-10-20T13:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/2c1c7e302fb4cc20/viridian-therapeutics-secures-300m-royalty-financing-to-advance-thyroid-eye-disease-therapies 2025-10-20T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/96a8d1fdb8ab1339/cyclana-bio-secures-ps5m-to-pioneer-tissue-level-drug-discovery-for-endometriosis 2025-10-20T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/10528bfe02cfc2fa/glaukos-receives-fda-approval-for-epioxa-first-incision-free-topical-therapy-for-keratoconus 2025-10-20T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/9971249701bde0b4/merck-breaks-ground-on-3-billion-pharmaceutical-manufacturing-center-of-excellence-in-virginia 2025-10-20T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/c6550284cb115ebe/pharming-group-to-present-12-studies-on-rare-disease-treatments-at-2025-acaai-meeting 2025-10-20T10:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/6cc60ba54c25141b/hengrui-pharma-debuts-exhibition-booth-at-esmo-2025-with-46-oncology-studies-across-14-therapeutic-programs 2025-10-20T10:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/61f03814b8ddb720/edx-medical-secures-ps4-million-funding-to-advance-cancer-diagnostic-pipeline 2025-10-20T10:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/72970a6716cfe115/pakistan-s-first-biopharma-plant-launches-tirzepatide-for-type-2-diabetes-and-obesity 2025-10-20T10:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/64caac9fcf9003e8/neuren-pharmaceuticals-receives-fda-fast-track-designation-for-nnz-2591-in-rare-neurological-syndromes 2025-10-20T06:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/abd59bb86f0767c5/carsgen-s-satri-cel-shows-promising-results-in-world-s-first-car-t-cell-adjuvant-therapy-trial-for-pancreatic-cancer 2025-10-20T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/b266983811945a12/monash-scientists-decode-rna-splicing-mechanisms-opening-path-to-personalized-mrna-therapies 2025-10-20T06:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/024617d9f5c24580/thermo-fisher-scientific-partners-with-openai-to-accelerate-drug-development-using-ai-technology 2025-10-20T06:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/37be8430f8eff0fc/discus-trial-shows-3-cycles-of-chemotherapy-improve-quality-of-life-without-compromising-efficacy-in-advanced-urothelial-cancer 2025-10-20T06:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/416b8c13a7ab0160/cspc-pharma-s-jskn003-receives-second-breakthrough-therapy-designation-in-china-for-her2-positive-colorectal-cancer 2025-10-20T06:17:37+00:00 hourly 0.9 https://trial.medpath.com/news/af609b8339363a93/kivu-bioscience-initiates-first-in-human-trial-of-kivu-107-next-generation-ptk7-targeting-adc-for-advanced-solid-tumors 2025-10-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c4be010cbe47820/dynamic-iii-trial-shows-promise-for-ctdna-guided-chemotherapy-de-escalation-in-stage-iii-colon-cancer 2025-10-20T03:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/85364873148deea9/clover-biopharmaceuticals-appoints-nicholas-jackson-as-president-of-global-r-d-to-advance-rsv-combination-vaccine-development 2025-10-20T03:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/aa5a01a820d99716/adjuvant-therapy-achieves-ctdna-clearance-in-26-of-colorectal-cancer-patients-improves-disease-free-survival 2025-10-19T21:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/4a3900bcf637e661/atezolizumab-shows-mixed-results-in-advanced-endometrial-cancer-trial-benefits-dmmr-patients 2025-10-19T21:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/87917b3e87f99448/fda-issues-second-complete-response-letter-to-xbrane-s-ranibizumab-biosimilar-application 2025-10-19T21:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/a5d9a04b29d9852b/dream3r-phase-3-trial-shows-promise-but-inconclusive-results-for-durvalumab-in-advanced-pleural-mesothelioma 2025-10-19T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/7dd4f28d430dd8be/ioncologi-secures-key-patent-for-rna-based-cancer-immunotherapy-as-studies-link-covid-19-mrna-vaccines-to-enhanced-checkpoint-inhibitor-response 2025-10-19T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/cdc49f2b7bd77cfd/mckesson-expands-oncology-distribution-network-with-lymphir-and-phyrago-partnerships 2025-10-19T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/00a7e86e72b870fc/moderna-s-mrna-flu-vaccines-show-promising-efficacy-and-safety-data-at-idweek-2025 2025-10-19T17:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/6001482b171271e0/daiichi-sankyo-s-ds-3939-shows-promising-early-results-in-advanced-solid-tumors-phase-1-2-trial 2025-10-19T17:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/35c5b0c8d88037c5/avelumab-shows-modest-activity-in-advanced-penile-cancer-but-fails-to-deliver-transformative-survival-benefits 2025-10-19T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/673e853e94288054/wuhan-yzy-biopharma-s-m701-shows-superior-efficacy-over-cisplatin-in-phase-ii-trial-for-malignant-pleural-effusion 2025-10-19T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/bb982b1c644b1527/capivasertib-shows-significant-survival-benefit-in-pten-deficient-metastatic-prostate-cancer 2025-10-19T17:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/dc9f14eb17e4194a/rapt-therapeutics-prepares-to-release-phase-2-data-for-rpt904-in-chronic-spontaneous-urticaria 2025-10-19T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/8128d8854b84967c/j-j-s-rybrevant-shows-45-response-rate-in-head-and-neck-cancer-doubling-standard-of-care 2025-10-19T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/38bf72ce554edc45/subcutaneous-amivantamab-shows-45-response-rate-in-recurrent-head-and-neck-cancer 2025-10-19T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/a1ff5eab3c6da857/therapeutic-cancer-vaccines-show-promise-for-pancreatic-cancer-treatment-despite-immunosuppressive-challenges 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5e8b2b8d6a729ed/nanomaterial-enhanced-mri-reveals-novel-biomarkers-for-hepatocellular-carcinoma-diagnosis-and-therapy 2025-10-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed71f0afcd145d49/pfizer-s-braftovi-plus-mektovi-achieves-nearly-four-year-survival-in-braf-mutant-lung-cancer 2025-10-19T14:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/d0adfec789b4a6b8/mrna-covid-19-vaccines-show-promise-in-enhancing-cancer-immunotherapy-survival-rates 2025-10-19T14:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/201934817acfa9cc/rsv-immunization-safe-for-infants-regardless-of-maternal-vaccination-status-new-study-shows 2025-10-19T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/7753c1c37859b0a3/carsgen-s-allogeneic-bcma-car-t-therapy-ct0596-shows-promising-results-in-rare-primary-plasma-cell-leukemia 2025-10-19T09:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/65995bb6d167918f/leap-014-trial-shows-lenvatinib-triple-combination-fails-to-improve-survival-in-metastatic-esophageal-cancer 2025-10-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/2fc18fdce33305ec/phase-3-trial-demonstrates-safety-and-efficacy-of-epithelium-on-corneal-cross-linking-for-keratoconus-treatment 2025-10-19T01:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/a6457bb402fbdeab/cork-biotech-arraypatch-wins-eur800k-seedcorn-award-for-revolutionary-microneedle-drug-delivery-technology 2025-10-19T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/910b16e45226d16e/cadonilimab-plus-chemotherapy-demonstrates-sustained-survival-benefit-in-advanced-gastric-cancer-final-analysis 2025-10-19T01:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/3ee228fd979d3c18/aurion-biotech-s-aurn001-cell-therapy-achieves-all-endpoints-in-phase-1-2-trial-for-corneal-endothelial-disease 2025-10-18T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/cf3d3a82227043f4/johnson-johnson-eyes-full-acquisition-of-protagonist-therapeutics-following-successful-icotrokinra-partnership 2025-10-18T21:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/6dfc94d4a001ddbd/il33-st2-axis-emerges-as-predictive-biomarker-for-anti-pd1-therapy-in-advanced-gastric-cancer 2025-10-18T21:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/ea37978671a57f6e/taysha-gene-therapies-faces-mounting-financial-pressure-amid-leadership-changes-and-operational-challenges 2025-10-18T21:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/af8c6f6f53cf65d3/xtr008-achieves-dramatic-progression-free-survival-benefit-in-advanced-gastroenteropancreatic-neuroendocrine-tumors 2025-10-18T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/43e19d84430f3e3e/invikafusp-alfa-shows-promise-in-checkpoint-inhibitor-resistant-solid-tumors-with-high-disease-control-rates 2025-10-18T21:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/80da5de8a34f7657/novel-monoclonal-antibody-mam01-demonstrates-complete-protection-against-malaria-in-phase-1-trial 2025-10-18T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/3bb934ea21e40a19/y-ora-vision-launches-with-novel-migs-device-for-glaucoma-treatment-following-seri-eyexora-licensing-deal 2025-10-18T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/6e0a391a311ec2b2/moderna-advances-mrna-4359-as-late-stage-oncology-asset-with-new-melanoma-data 2025-10-18T17:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/b46ec5f74bb228a5/scg142-demonstrates-100-disease-control-rate-in-first-in-human-trial-for-hpv-associated-cancers 2025-10-18T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/bdde620804d8bd00/keytruda-plus-lenvima-shows-durable-5-year-survival-benefit-in-advanced-endometrial-cancer 2025-10-18T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/635df2c773f4a32f/vimseltinib-shows-durable-two-year-efficacy-in-tenosynovial-giant-cell-tumor-phase-3-trial 2025-10-18T17:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/46ecd439259ecc5f/india-develops-first-indigenous-antibiotic-nafithromycin-for-resistant-respiratory-infections 2025-10-18T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/e2e3bc6dde979677/fda-approves-first-iron-based-contrast-agent-for-brain-mri-imaging 2025-10-18T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/d6f41aaad959681b/topical-vaginal-drug-therapy-shows-promise-as-novel-cervical-cancer-treatment-approach 2025-10-18T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/ef2896964dd39d48/celcuity-reports-promising-phase-1-results-for-gedatolisib-darolutamide-combination-in-metastatic-prostate-cancer 2025-10-18T13:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/145620daabe3a51d/precede-biosciences-unveils-liquid-biopsy-platform-for-small-cell-lung-cancer-target-expression-at-esmo-2025 2025-10-18T13:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/aed56ea7e5f3e20c/salubris-biotherapeutics-reports-promising-phase-1-results-for-5t4-targeted-adc-jk06-in-advanced-solid-tumors 2025-10-18T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/dbe1c1e7b125c27d/nurix-therapeutics-nx-1607-shows-49-3-disease-control-rate-in-first-in-class-cbl-b-inhibitor-trial 2025-10-18T13:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/af69f84f5bb31779/pherflot-trial-achieves-48-complete-response-rate-in-her2-positive-gastric-cancer 2025-10-18T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/c66ad2a84cf59a1e/roche-acquires-hansoh-s-cdh17-targeting-adc-hs-20110-in-1-45-billion-deal 2025-10-18T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/5e72104b4897f3c9/doxypep-shows-mixed-results-against-stis-as-resistance-concerns-mount-in-clinical-studies 2025-10-18T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/958c17e8c128a73b/uspto-director-takes-direct-control-of-patent-challenge-reviews-potentially-strengthening-patent-protection 2025-10-18T09:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/bb835da069c397f1/lenvatinib-everolimus-combination-outperforms-cabozantinib-in-second-line-kidney-cancer-treatment 2025-10-18T09:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/d3f6513a61bbacb4/rituximab-shows-promise-for-treatment-resistant-hypersensitivity-pneumonitis-in-new-study 2025-10-18T00:48:48+00:00 hourly 0.9 https://trial.medpath.com/news/160a34633b688957/ponsegromab-shows-sustained-weight-gain-in-cancer-cachexia-patients-over-64-week-extension-study 2025-10-18T00:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/13aa99486efef0d0/cardiol-therapeutics-secures-11m-funding-to-advance-heart-disease-pipeline-following-breakthrough-archer-trial-results 2025-10-18T00:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/5dbf40c168a88c4e/major-pharma-consortium-develops-digital-endpoint-for-atopic-dermatitis-clinical-trials 2025-10-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb17a9cd02eaf525/rutgers-scientists-identify-mitochondrial-mechanism-behind-venetoclax-resistance-in-acute-myeloid-leukemia 2025-10-17T22:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/3bb0b3ad24a9dff5/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-novel-stroke-therapy-scp776 2025-10-17T22:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/bdb48610486c7f06/imunon-s-dna-vaccine-shows-superior-durability-over-mrna-vaccines-in-phase-1-covid-19-trial 2025-10-17T22:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/ef489804d093963f/zongertinib-shows-77-response-rate-in-first-line-treatment-of-her2-mutant-lung-cancer 2025-10-17T22:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/a25484a5a5bee93b/serum-cd80-emerges-as-predictive-biomarker-for-neoadjuvant-immunotherapy-response-in-esophageal-cancer 2025-10-17T22:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/7f7d694ebf4b486e/comprehensive-analysis-of-checkpoint-inhibitor-pneumonitis-reveals-key-risk-factors-and-management-patterns-across-25-nivolumab-trials 2025-10-17T21:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/e9385e39f4e7474e/abvc-biopharma-reports-1-27-million-q3-licensing-revenue-as-cns-pipeline-advances-toward-phase-iii 2025-10-17T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/d96f3ebee6e8d88f/disc-medicine-to-present-phase-2-rally-mf-trial-data-for-disc-0974-in-myelofibrosis-associated-anemia-at-ash-2025 2025-10-17T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/cede39a6a1cb3d85/dovato-demonstrates-non-inferior-efficacy-to-biktarvy-with-significantly-less-weight-gain-in-96-week-hiv-treatment-study 2025-10-17T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/d0e3817c32e8b366/corvus-pharmaceuticals-reports-promising-interim-data-for-ciforadenant-triple-therapy-in-metastatic-renal-cell-cancer 2025-10-17T17:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/870e708c0e423e01/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-cell-therapy-in-refractory-rheumatoid-arthritis 2025-10-17T17:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/dd29e2c0fe22a36e/phase-3-alban-trial-shows-atezolizumab-plus-bcg-fails-to-improve-outcomes-in-high-risk-bladder-cancer 2025-10-17T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/25e9c6a65f1e1988/itm-to-present-phase-3-compete-trial-subgroup-analyses-at-nanets-2025-highlighting-177lu-edotreotide-success-in-gep-nets 2025-10-17T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/f8ef8567880389f7/ucl-scientists-engineer-gdt-cells-to-target-chemotherapy-resistant-bowel-cancer 2025-10-17T17:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/2a3a5f2be906d9b5/regeneron-s-gene-therapy-shows-remarkable-success-in-treating-inherited-deafness 2025-10-17T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/81e09dd9ab7ee914/pimicotinib-shows-deepening-tumor-responses-in-tgct-patients-with-76-2-response-rate-at-extended-follow-up 2025-10-17T17:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/8db95703d5cd13ce/fda-grants-orphan-drug-designation-to-kiniksa-s-kpl-387-for-pericarditis-treatment 2025-10-17T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/6bc028b9786048dd/multitude-therapeutics-reports-promising-phase-i-ii-results-for-cd44v9-directed-adc-amt-116-in-advanced-solid-tumors 2025-10-17T17:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/a97b3963d7634f97/pin1-inhibitors-demonstrate-novel-antiviral-mechanism-against-hsv-1-by-trapping-virus-in-cell-nucleus 2025-10-17T17:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/2826e4c5e812a9d8/fda-approves-sir-spheres-y-90-resin-microspheres-for-unresectable-hepatocellular-carcinoma 2025-10-17T17:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/3db3365c5908862a/tonix-pharmaceuticals-reports-promising-preclinical-data-for-tnx-801-mpox-vaccine-at-world-vaccine-congress 2025-10-17T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/ce89e8a752aa8f71/boston-scientific-to-acquire-nalu-medical-for-533-million-expanding-peripheral-nerve-stimulation-portfolio 2025-10-17T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/8afcb2240365c42c/european-regulators-reject-sanofi-s-rezurock-for-chronic-graft-vs-host-disease-treatment 2025-10-17T14:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/db66b8d7b5a9dbff/parabilis-medicines-achieves-first-ever-clinical-success-targeting-undruggable-b-catenin-tcf-interaction-with-fog-001 2025-10-17T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/84e120015da346f7/fda-approves-expanded-pediatric-indications-for-yuflyma-biosimilar-extending-treatment-options-for-adolescent-hidradenitis-suppurativa-and-pediatric-uveitis 2025-10-17T13:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/f095828bd7c8d5e5/ema-rejects-extended-dosing-regimen-for-fabry-disease-treatment-elfabrio 2025-10-17T13:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/6bfef645ecafda4f/fda-mandates-dpyd-genetic-testing-before-capecitabine-chemotherapy-to-prevent-fatal-toxicity 2025-10-17T09:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/a3cd45bcba317230/cstone-pharmaceuticals-receives-positive-ema-opinion-for-sugemalimab-in-stage-iii-nsclc 2025-10-17T09:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/b2cc0ee6b7284a0a/nice-approves-long-acting-hiv-prevention-injection-for-england-and-wales 2025-10-17T09:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/4acf8a31ebd7933a/abbvie-s-rinvoq-becomes-first-oral-jak-inhibitor-approved-for-giant-cell-arteritis-as-novartis-cosentyx-fails-phase-iii-trial 2025-10-17T05:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/ab21c105f1f55247/dompe-receives-fda-priority-voucher-for-intranasal-ngf-therapy-targeting-naion-vision-loss 2025-10-17T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/6f51cb110767f61d/samsung-invests-110-million-in-grail-to-bring-multi-cancer-blood-test-to-asia 2025-10-17T05:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/37bd710688006fee/i-mab-announces-strategic-transformation-to-novabridge-biosciences-with-hong-kong-ipo-plans-and-vis-101-acquisition 2025-10-17T01:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/e43d2f90a1359424/fda-approves-second-generic-mifepristone-despite-political-opposition 2025-10-17T01:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/1f2a6912a3952d1d/trump-administration-secures-deal-with-emd-serono-to-cut-fertility-drug-prices-by-up-to-84 2025-10-17T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/03e44c38e0488dc5/artiva-s-allonk-receives-fda-fast-track-designation-for-refractory-rheumatoid-arthritis 2025-10-17T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/06c6e6c7720cc020/large-french-study-confirms-mrna-covid-19-vaccines-safe-during-early-pregnancy-no-increased-birth-defect-risk 2025-10-17T01:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/f2e11a85483c4ad1/immunai-and-astrazeneca-expand-partnership-with-85m-ibd-target-discovery-deal 2025-10-17T01:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/5537a5a0ca3d5a0c/vanderbilt-researcher-develops-ai-framework-to-overcome-drug-discovery-generalization-challenge 2025-10-17T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/20cddadfd192841e/dna-based-sensor-enables-5-minute-drug-monitoring-from-single-blood-drop-at-home 2025-10-17T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/413c3565ba7da882/fda-grants-breakthrough-therapy-designation-to-bpl-003-nasal-spray-for-treatment-resistant-depression 2025-10-17T01:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/5756bcc9e2347886/kezar-life-sciences-faces-fda-setback-for-autoimmune-hepatitis-drug-explores-strategic-alternatives 2025-10-16T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/8916b3373a655158/aligos-therapeutics-receives-usan-approval-for-pevifoscorvir-sodium-first-generic-name-for-hepatitis-b-drug-candidate 2025-10-16T21:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/dbf70d5806d4f26a/california-launches-first-state-branded-insulin-program-offering-55-five-pack-to-combat-high-drug-costs 2025-10-16T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/86979d7c27322250/fda-issues-safety-alert-on-radiofrequency-microneedling-devices-following-reports-of-severe-complications 2025-10-16T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/c74cbf309fd4ee3e/allergy-therapeutics-reports-positive-progress-in-phase-2a-trial-of-vlp-peanut-allergy-vaccine 2025-10-16T21:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/36a9bf0cb81fefa3/cellectis-reports-promising-phase-1-results-for-lasme-cel-in-relapsed-refractory-b-all-advances-to-pivotal-phase-2 2025-10-16T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/44510b36179a39e5/thymic-health-emerges-as-novel-biomarker-for-predicting-immunotherapy-response-across-cancer-types 2025-10-16T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/9e7584e32e1fb07c/xbrane-biopharma-secures-sek-60-million-conditional-financing-ahead-of-lucamzi-fda-decision 2025-10-16T21:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/04ba46f69febedd6/extended-release-oral-minoxidil-shows-promise-as-first-fda-approved-hair-loss-treatment-for-women 2025-10-16T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/ed45acd5fcc3b352/uspto-proposes-major-restrictions-on-inter-partes-review-patent-challenges 2025-10-16T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/896744c55c1cb2f4/veeva-systems-and-openevidence-partner-to-launch-ai-powered-clinical-trial-access-platform 2025-10-16T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/150238b8ba782a6e/gene-therapy-achieves-95-success-rate-in-treating-ada-scid-bubble-boy-disease 2025-10-16T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/c504c2f048d961b2/akari-therapeutics-secures-5-million-financing-to-advance-novel-adc-platform-with-spliceosome-modulator-payload 2025-10-16T17:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/b2d925db3bf41fb4/bridgene-biosciences-secures-28-million-series-b-funding-to-advance-tead-inhibitor-bgc-515-toward-phase-2 2025-10-16T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/93194e5eedebf3d9/genentech-launches-direct-to-patient-program-for-xofluza-offering-70-price-reduction 2025-10-16T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/5469f801d103d5f4/me-therapeutics-secures-exclusive-license-for-cd22-nanobody-technology-to-advance-next-generation-car-cell-therapies 2025-10-16T17:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/ba205c59b49a0245/taiho-pharmaceutical-exercises-option-for-casdatifan-hif-2a-inhibitor-in-asia-pacific-territories 2025-10-16T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/672e399265c59d78/first-parkinson-s-patient-shows-significant-motor-improvement-with-ux-da001-autologous-cell-therapy 2025-10-16T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/b6d7898ea2b90b1e/researchers-plan-fda-application-for-groundbreaking-crispr-base-editing-trial-following-baby-kj-s-successful-treatment 2025-10-16T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/e1f7ae3fdef95b6e/advancell-appoints-alpha-therapy-pioneer-andrew-kay-as-board-chair-to-lead-psma-targeted-radiopharmaceutical-development 2025-10-16T17:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/38f4a8c57c1597d3/esperion-advances-esp-2001-for-primary-sclerosing-cholangitis-targeting-1-billion-market-opportunity 2025-10-16T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/ad1605254fdce788/us-orphan-drug-market-poised-to-exceed-190-billion-by-2030-as-fda-designations-accelerate-rare-disease-therapy-development 2025-10-16T17:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/4d0debcbbce9a963/calico-appoints-former-abbvie-executive-philip-kym-as-head-of-drug-discovery-to-advance-anti-aging-therapeutics 2025-10-16T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/fbe935bb891c44ec/doron-therapeutics-initiates-phase-3-trial-of-motys-biologic-therapy-for-knee-osteoarthritis 2025-10-16T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/2739282d0c4f51be/imbria-pharmaceuticals-partners-with-patient-advocacy-group-to-accelerate-recruitment-for-novel-heart-disease-trial 2025-10-16T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/1d3370691d879a05/sunshine-biopharma-launches-generic-pravastatin-in-canada-through-nora-pharma-subsidiary 2025-10-16T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/02cc64c58153743a/senescent-immune-cells-drive-immunotherapy-resistance-in-cancer-through-sasp-mediated-tumor-microenvironment-remodeling 2025-10-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae34e6b152124ba4/foghorn-therapeutics-reports-breakthrough-progress-in-selective-arid1b-degrader-for-cancer-treatment 2025-10-16T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/dc48fb567d66adcd/halda-therapeutics-hld-0915-shows-promising-first-in-human-results-in-advanced-prostate-cancer 2025-10-16T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/47d1bfeceb1cbe0d/google-deepmind-s-ai-model-discovers-novel-cancer-immunotherapy-approach-through-cell-level-analysis 2025-10-16T13:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/e4905db42c09ee3f/sglt-2-inhibitors-show-11-reduction-in-autoimmune-disease-risk-in-large-korean-study 2025-10-16T13:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/7f091036bd5828d3/veradermics-secures-150-million-series-c-to-advance-first-extended-release-oral-minoxidil-through-phase-3-trials 2025-10-16T13:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/c411e11808dd468e/dianthus-therapeutics-secures-exclusive-license-for-dnth212-a-dual-target-autoimmune-therapy 2025-10-16T13:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/1c8a79019da1a617/graph-ai-secures-3m-seed-funding-to-transform-drug-safety-monitoring-with-ai-native-platform 2025-10-16T13:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/40bbf0fca9bc46e8/astellas-vyloy-fails-phase-2-pancreatic-cancer-trial-despite-gastric-cancer-success 2025-10-16T13:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/ae3a7997e94725aa/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-phase-2-3-trial-for-prosthetic-joint-infections 2025-10-16T13:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/84a1c352ba464758/praxis-precision-medicines-reports-positive-phase-3-results-for-ulixacaltamide-in-essential-tremor 2025-10-16T13:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/ea579586223bdcbc/adcytherix-secures-eur105m-series-a-to-advance-novel-adc-pipeline-into-clinical-trials 2025-10-16T13:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/97e341d20009acf1/california-accelerates-psychedelic-research-for-ptsd-treatment-following-veteran-backed-legislation 2025-10-16T13:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/f557aaacc2d28bf4/world-s-largest-parkinson-s-clinical-trial-platform-launches-in-uk-testing-multiple-disease-modifying-therapies-simultaneously 2025-10-16T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/b1e3ef233fc38459/critical-path-institute-launches-disease-modeling-coalition-to-accelerate-pediatric-ibd-drug-development 2025-10-16T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/ce9b310765d24d35/biocon-biologics-and-civica-expand-partnership-to-launch-private-label-insulin-glargine-in-us-market 2025-10-16T13:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/7d214c42dd0cc5cd/intensity-therapeutics-raises-4-million-to-advance-intratumoral-cancer-therapy-clinical-trials 2025-10-16T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a78f44676aeec01/clearb-therapeutics-advances-clb-4000-therapeutic-vaccine-for-chronic-hepatitis-b-after-positive-sentinel-safety-review 2025-10-16T09:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/a6c8abeba1919459/enterome-s-eo2463-receives-fda-fast-track-designation-for-follicular-lymphoma-watch-and-wait-treatment 2025-10-16T09:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/15c448cfd715200e/solvonis-secures-ps1-25-million-funding-to-advance-cns-drug-development-pipeline 2025-10-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/8e3b66cf7dc961a0/18-million-dod-funded-trial-to-test-metformin-for-idiopathic-pulmonary-fibrosis-in-veterans 2025-10-16T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/f521d80b02d9be1f/pelage-pharmaceuticals-secures-120m-series-b-to-advance-hair-loss-stem-cell-therapy-toward-phase-iii 2025-10-16T05:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/2ccb643ed50aecb0/step-pharma-secures-eur38-million-series-c-to-advance-ctps1-inhibitor-dencatistat-across-multiple-cancer-indications 2025-10-16T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/194fa67f53ad6b5c/innocan-pharma-secures-patent-for-lpt-cbd-technology-in-japan-s-102-billion-pharmaceutical-market 2025-10-16T01:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/ff2a4d36ce12e070/viatris-acquires-aculys-pharma-gains-rights-to-cns-therapies-pitolisant-and-spydia-in-japan 2025-10-16T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/c23d2f67d4f2b79f/gene-therapy-achieves-95-success-rate-in-treating-children-with-rare-immune-disorder-ada-scid 2025-10-16T01:17:30+00:00 hourly 0.9 https://trial.medpath.com/news/ffff482c785709a2/brain-metastasis-from-breast-cancer-pipeline-shows-promise-with-10-therapies-in-development 2025-10-16T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/128ae030186f561c/smartlens-raises-5-2-million-to-advance-fda-clearance-of-electronics-free-contact-lens-for-continuous-glaucoma-monitoring 2025-10-16T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/9f80ea92d25a645b/rapid-sublocade-induction-shows-superior-patient-retention-in-opioid-use-disorder-treatment 2025-10-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9b3f3639b013a5d8/liberate-bio-achieves-first-in-vivo-car-m-b-cell-depletion-in-non-human-primates 2025-10-15T21:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/4e462be297d210a3/rna-sequencing-guided-treatment-selection-shows-promise-in-metastatic-renal-cell-carcinoma 2025-10-15T21:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/b096d9fb039c72ba/scisparc-transfers-11-6m-cns-drug-portfolio-to-canadian-public-company-in-strategic-restructuring 2025-10-15T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/52136b384fc8b836/cd19-car-t-cell-therapy-demonstrates-promising-activity-in-richter-transformation-despite-modest-outcomes 2025-10-15T21:20:41+00:00 hourly 0.9 https://trial.medpath.com/news/de208e9f7a9ac223/dual-cd19-cd22-car-t-therapy-achieves-durable-remission-in-refractory-plasmablastic-lymphoma-case 2025-10-15T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/fdecc3441e04d80d/absci-accelerates-abs-201-hair-loss-treatment-trial-announces-expert-seminar-for-december 2025-10-15T21:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/e421201bd50b789c/first-gene-therapy-targeting-brain-white-matter-shows-breakthrough-results-in-fatal-childhood-disease 2025-10-15T21:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/d62ab0f50b6e5a93/crispr-therapy-reduces-influenza-a-viral-load-by-50-in-human-lung-chip-model 2025-10-15T21:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/eadc5ef544f7911b/pelage-pharmaceuticals-raises-120-million-for-novel-hair-loss-therapy-targeting-stem-cell-regeneration 2025-10-15T21:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/d032d5b5db62a956/essilorluxottica-acquires-ai-powered-retinai-to-advance-eye-disease-diagnosis-and-drug-development 2025-10-15T21:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/bfc0f4774120fb45/fda-grants-fast-track-status-to-enterome-s-eo2463-for-follicular-lymphoma-treatment 2025-10-15T21:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/be252d2fb06c3f91/fda-approves-first-1-minute-hiv-self-test-revolutionizing-at-home-diagnostics 2025-10-15T21:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/5c97455a56fb6836/peptidream-pdradiopharma-and-curium-initiate-registrational-trial-for-64cu-psma-i-t-in-japanese-prostate-cancer-patients 2025-10-15T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/30c0690768b280d2/cleveland-clinic-partners-with-khosla-ventures-to-accelerate-healthcare-innovation-through-strategic-collaboration 2025-10-15T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/18f31036c364e144/mmi-launches-largest-u-s-clinical-trial-for-robotic-microsurgery-with-first-patient-enrollment 2025-10-15T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/728b075442922bd3/sk-bioscience-initiates-first-in-human-trial-for-universal-coronavirus-vaccine-gbp511 2025-10-15T17:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/c6eefe9a828002dc/fda-accepts-chiesi-s-new-drug-application-for-triple-combination-asthma-inhaler 2025-10-15T17:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/4b6b0d3d61e0b3b8/biomarker-analysis-identifies-predictors-of-long-term-survival-in-glioblastoma-patients-receiving-survaxm-immunotherapy 2025-10-15T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/986330c1f7b286ad/jacobio-pharma-secures-rmb-200-million-strategic-partnership-with-oceanpine-capital-to-advance-kras-oncology-pipeline 2025-10-15T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/7d78fa6e7a360d58/novo-nordisk-acquires-zaltenibart-from-omeros-for-up-to-2-1-billion-to-target-rare-blood-and-kidney-disorders 2025-10-15T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/00f157a980937be8/merck-acquires-jsr-life-sciences-chromatography-business-to-strengthen-protein-a-purification-capabilities 2025-10-15T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/d73a5cbb81f93153/enveric-biosciences-engages-ip-firm-to-defend-patent-claims-related-to-abbvie-s-1-2-billion-bretisilocin-acquisition 2025-10-15T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/322bb26a4f2e4c57/syngene-international-expands-peptide-manufacturing-and-automation-capabilities-to-accelerate-drug-development 2025-10-15T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/ad77524b85ac0c45/eikon-therapeutics-to-present-phase-2-data-on-novel-tlr7-8-co-agonist-eik1001-for-advanced-nsclc-at-esmo-2025 2025-10-15T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/9296acaa74722804/rocket-doctor-ai-secures-2m-nih-grant-to-develop-ai-powered-family-medical-history-tool-for-health-equity 2025-10-15T17:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/d0081717ec876f99/oncodesign-precision-medicine-secures-eur250000-regional-grant-to-advance-cancer-drug-development 2025-10-15T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/43ef83134785ec21/oncohost-s-prophet-model-shows-promise-for-optimizing-melanoma-treatment-selection-at-esmo-2025 2025-10-15T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/4ff8b3cbb97654d1/fda-grants-fast-track-designation-to-ng-350a-for-mismatch-repair-proficient-locally-advanced-rectal-cancer 2025-10-15T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/ea004b1c0b078127/anteris-technologies-receives-european-regulatory-clearance-for-duravr-global-pivotal-trial-in-aortic-stenosis 2025-10-15T17:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/e9c502d05652039b/nice-rejects-vorasidenib-for-nhs-use-despite-positive-brain-cancer-trial-results 2025-10-15T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/f436d68bda5c0dc8/fda-approves-pivotal-trial-for-novel-tricuspid-valve-repair-device-mia-t 2025-10-15T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/ddca7f372f9f22bc/landmark-bio-partners-with-mass-general-brigham-to-accelerate-cell-and-gene-therapy-development 2025-10-15T13:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/4404c0dc7db386ac/mission-therapeutics-secures-13-3m-to-advance-first-in-class-parkinson-s-disease-drug-mtx325-into-phase-ib-trials 2025-10-15T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/15111d4f2823956d/regeneron-presents-new-libtayo-data-at-esmo-2025-showcasing-patient-centric-every-6-week-dosing-for-high-risk-skin-cancer 2025-10-15T13:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/154cff72ea89b487/mrna-delivered-nanobodies-show-promise-against-colorectal-cancer-in-preclinical-study 2025-10-15T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/bccb142ae6c9f016/neoadjuvant-radiotherapy-shows-survival-benefit-in-locally-advanced-rectal-cancer-despite-increased-stoma-risk 2025-10-15T13:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/4d45bf0adfeffa85/anti-pd-1-immunotherapy-shows-promise-for-drug-free-hiv-control-in-phase-1-trial 2025-10-15T13:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/cef4e02ab779debc/hanmi-pharmaceutical-s-dual-ezh1-2-inhibitor-shows-promising-antitumor-activity-in-phase-1-trial 2025-10-15T13:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/596989832f31f6bd/transpire-bio-receives-fda-orphan-drug-designation-for-inhaled-therapies-targeting-ipf-and-glioblastoma 2025-10-15T13:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/1a0e5a46afd6c845/bexorg-secures-42-5m-to-revolutionize-cns-drug-discovery-with-ai-powered-whole-human-brain-platform 2025-10-15T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/3aec1c7fb05da3f8/indivi-and-clouds-of-care-partner-to-advance-deep-phenotyping-technologies-for-alzheimer-s-and-parkinson-s-drug-development 2025-10-15T13:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/c2ba87eb3e65b28c/omnix-medical-raises-25-million-series-c-to-advance-novel-antimicrobial-against-drug-resistant-infections 2025-10-15T13:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/7d0e7f5aa3e5db1b/caps-medical-s-plasmasure-system-receives-fda-breakthrough-device-designation-for-non-muscle-invasive-bladder-cancer-treatment 2025-10-15T13:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/b46f7775e34b2631/lisaftoclax-shows-promise-in-relapsed-multiple-myeloma-and-al-amyloidosis-across-cytogenetic-profiles 2025-10-15T13:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/ff0e9ad65bb2e07e/pfizer-s-tukysa-achieves-phase-iii-success-in-her2-positive-breast-cancer-maintenance-therapy 2025-10-15T13:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/4e8ca022b83ae647/mabwell-s-b7-h3-targeting-adc-7mw3711-shows-promising-efficacy-in-advanced-solid-tumors 2025-10-15T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/b3c7ba163d9b4df7/spyglass-pharma-s-bim-iol-system-shows-42-iop-reduction-at-24-months-in-glaucoma-patients 2025-10-15T09:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/526a08e522bb8ed0/combined-mrna-therapy-shows-promise-for-preventing-respiratory-distress-in-preterm-infants 2025-10-15T09:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/a2cb344986379b5e/celltrion-secures-first-mover-advantage-in-new-zealand-with-stelara-biosimilar-steqeyma-approval 2025-10-15T09:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/905fffe5266f4e8f/dnmt-inhibitors-combined-with-anti-pd-1-therapy-show-promise-for-refractory-nk-t-cell-lymphoma 2025-10-15T09:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/1c3cfb10eacd9571/propanc-biopharma-secures-100-million-financing-to-advance-cancer-stem-cell-therapy-prp-toward-first-in-human-trial 2025-10-15T08:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/a29ef328962a69ad/nona-biosciences-appoints-dr-di-hong-as-ceo-to-advance-antibody-discovery-platform 2025-10-15T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/0c95b6a1ff1e8bed/orum-therapeutics-strengthens-degrader-antibody-conjugate-platform-with-key-executive-appointment 2025-10-15T05:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/153bf905b3d94a6d/skin-elements-raises-2-5-million-to-commercialize-se-formula-biotechnology-platform 2025-10-15T05:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/fbf36e28292e006b/nucana-reports-durable-responses-with-nuc-3373-plus-pembrolizumab-in-heavily-pre-treated-cancer-patients 2025-10-15T01:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/699147216c4bf08c/hyperpolarized-nmr-reveals-real-time-metabolic-dynamics-in-car-t-cell-manufacturing 2025-10-15T01:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/4577268b5fe10d9d/privo-technologies-completes-phase-2-run-in-for-prv111-oral-cancer-patch-shows-promise-for-surgery-sparing-treatment 2025-10-15T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/caf25aec6c091b8e/uk-s-innovative-licensing-and-access-pathway-awards-first-innovation-passports-to-three-rare-disease-therapies 2025-10-15T01:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/41a54e2966aff5d4/ou-health-stephenson-cancer-center-doubles-phase-1-clinical-trial-capacity-with-35-million-federal-investment 2025-10-15T01:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/55487d18b61cfbdc/alleviate-health-raises-4-3m-to-transform-clinical-trial-patient-recruitment-with-ai-technology 2025-10-15T01:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/4a91beb4c84b2cb9/sonoma-biotherapeutics-reports-promising-phase-1-results-for-car-treg-therapy-in-refractory-rheumatoid-arthritis 2025-10-14T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/3f997e19c060b003/johnson-johnson-ceo-confirms-no-drug-pricing-agreement-with-white-house-despite-ongoing-negotiations 2025-10-14T21:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/806e14e45c845fe0/forlong-biotechnology-receives-milestone-payment-as-partner-s-fbody-r-fusion-protein-therapy-advances-to-ind-submission 2025-10-14T21:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/19c49088badb2b05/bicara-therapeutics-receives-fda-breakthrough-therapy-designation-for-head-and-neck-cancer-treatment 2025-10-14T21:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/2647023488c248a0/start-opens-spain-s-first-pediatric-onco-hematology-clinical-research-unit-in-madrid 2025-10-14T21:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/9903a249eb78abd3/corventum-receives-fda-ind-clearance-for-cvt-130-first-in-class-cardioprotective-agent-for-anthracycline-chemotherapy 2025-10-14T21:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/91e8414056f319dc/crism-s-chemoseed-platform-shows-72-cancer-cell-kill-rate-in-prostate-cancer-preclinical-studies 2025-10-14T21:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/b8e65565596bb6e3/bayer-s-hyrnuo-receives-fda-approval-for-her2-mutated-non-small-cell-lung-cancer 2025-10-14T21:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/3ee2e49499e414de/fuzzle-submits-novel-oral-device-for-fda-review-as-non-invasive-obesity-treatment 2025-10-14T21:16:04+00:00 hourly 0.9